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The metabolic syndrome is defined as a cluster of multiple metabolic abnormalities 
including obesity, insulin resistance, dyslipidemia and hypertension that co-occur more 
often than might be expected by chance. Since these abnormalities are all well documented 
risk factors for cardiovascular disease, the increasing prevalence of the metabolic syndrome 
in Western societies is a cause for major concern 1. Diet (e.g. consumption of fruit and 
vegetables and alcohol), lifestyle factors (e.g. smoking and physical exercise) 2 and genetic 
makeup 3, 4 influence the susceptibility to develop the metabolic syndrome. 
Obesity, in particular visceral obesity, is one of the defining components of the metabolic 
syndrome. Obesity is a condition in which body fat has accumulated to such an extent that it 
may impair health. Body Mass Index (BMI), weight in kilograms divided by the square of the 
height in meters (kg/m2), is a simple index to classify overweight and obesity in adults. Adults 
with a BMI ≥ 25 are defined as overweight and adults with a BMI ≥ 30 are classified as obese, 
according to the guidelines of the World Health Organization (WHO). In 2008 1.5 billion adults 
were overweight. Of these, over 200 million men and nearly 300 million women were obese 5. 
Adipose tissue plays a central role in the development of the metabolic syndrome. Under 
normal, healthy conditions, adipose tissue stores the excess of nutrients in the form of fat 
and releases energy under conditions of shortage. Under pathophysiological conditions fat 
may be disposed in non-adipose tissue (ectopic fat deposition), which will contribute to 
the pathogenesis of the metabolic syndrome. Excessive adipose tissue expansion may also 
lead to the development of pathogenic adipose tissue, characterized by chronic low-grade 
inflammation, which eventually may affect the systemic inflammatory status 6 7. This systemic 
pro inflammatory status can also contribute to the pathogenesis of the metabolic syndrome by 
affecting peripheral organs such as the liver, causing hypertriglyceridemia 8 or the vasculature, 
causing atherosclerosis 9. In this thesis, I have focused on changes in fatty acid (FA) metabolism 
and inflammatory status to investigate the effects on obesity, fat deposition, insulin resistance 
and hypertriglyceridemia, all components of the metabolic syndrome. 
Insulin resistance is a condition in which tissues of the body do not respond adequately 
to the actions of insulin 10. As a result, insulin induced transport of glucose across the cell 
membrane into muscle, adipose tissue and heart is impaired 11 12 13. In the liver, insulin 
inhibits glucose production and insulin resistance compromises the inhibition of glucose 
production by the liver 14. This results in fasting and postprandial hyperglycemia. Besides 
the effects on glucose metabolism, insulin resistance also influences lipid metabolism. 
Insulin resistance is associated with increased secretion of triglycerides (TG) by the liver 15 
and with increased secretion of FA from adipose tissue 16. Both of these altered conditions 
can result in hypertriglyceridemia. 
In this chapter, FA metabolism is introduced and the role of FA in the pathology of 
insulin resistance is discussed. Subsequently, metabolic inflammation is introduced, as well 
as its role in insulin resistance. 
1.1 INTRODUCTION
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Dyslipidemia is an important characteristic of the metabolic syndrome and specifically, 
elevated plasma TG and decreased high density lipoprotein (HDL) cholesterol 17. TG, which 
is composed of glycerol and three FA, and cholesterol are common lipids in our diet and are 
essential for life because they provide energy and are needed for proper cellular functioning. 
Lipids are hydrophobic molecules that are insoluble in an aqueous environment such as 
blood. Therefore, after absorption in the intestine, TG and cholesterol are packed into 
water-soluble particles called lipoproteins. These lipoproteins have a hydrophobic inner 
core, containing TG and cholesteryl esters (CE), that is covered by a shell of hydrophilic 
phospholipids (PL), unesterified cholesterol and proteins, termed apolipoproteins. 
Lipoproteins are divided into 5 classes, according to their origin and density: chylomicrons, 
very low density lipoproteins (VLDL), intermediate density lipoproteins (IDL), low 
density lipoproteins (LDL) and high density lipoproteins (HDL). The metabolism of these 
lipoproteins and the subsequent distribution and cellular processing of TG derived FA is 
described in the following sections and a schematic overview is depicted in Figure 1. In 
addition, the role of FA in the pathogenesis of insulin resistance will be discussed. 
1.2 FATTY ACID METABOLISM
Figure 1. Schematic overview of lipoprotein metabolism. See text for explanation. CE, 
cholesteryl ester; CETP, cholesteryl ester transfer protein; FC, free cholesterol; FA, fatty acids; 
LCAT, lechitin:cholesterol acyltransferase; LDLr, LDL receptor; LPL, lipoprotein lipase; LRP, 















In the intestine, dietary lipids are emulsified by bile acids and subsequently lipolysed 
by pancreatic lipase to glycerol and FA 18. FA are absorbed by the epithelial cells of the 
small intestinal villi, named enterocytes. Inside the enterocytes FA are re-esterified to TG 
and chylomicrons are formed: very large particles that consist mainly of TG, but also of 
cholesterol, phospholipids and apoproteins (apoAI, apoAIV, apoB48, apoCI, apoCII, 
apoCIII and apoE) 19. Chylomicrons are secreted into the lymph, from which they are 
transported to the blood circulation. 
In the fasting state, the liver is the main site of cholesterol and TG secretion. The 
liver secrets lipids in the form of VLDL particles. VLDL particles are formed within the 
endoplasmatic reticulum (ER) of hepatocytes where microsomal triglyceride transfer 
protein (MTP) transfers lipids onto apoB, thereby forming a pre-VLDL particle. This 
pre-VLDL particle undergoes a second step of lipidation in the Golgi system and is 
subsequently secreted as mature TG-rich particle 20. The lipids that are used for loading 
onto apoB originate from lipoprotein remnants, adipose tissue or can be synthesized de 
novo by the liver itself 21. When the VLDL particles have entered the bloodstream, they 
become enriched with apoCI, apoCII, apoCIII and apoE 22. 
HDL is needed for the removal of excess cholesterol from peripheral tissues back to the liver. 
Nascent HDL is produced by the liver and intestine from apoAI and PL. This HDL particle can 
take up cholesterol from various tissues via ATP-binding cassette transporter A1 (ABCA1) 23. 
Cholesterol is subsequently esterified by lecithin:cholesterol acyltransferase (LCAT) into CE 
that are stored in the core of HDL. Due to cholesterol accumulation, the HDL particle expands 
and matures into spherical HDL 24. HDL-derived cholesterol can be taken up by the liver and 
secreted in the bile, thus maintaining cholesterol homeostasis 25. HDL can exchange lipids with 
other lipoproteins via interaction with phospholipid transfer protein (PLTP), which facilitates 
the transport of PL from chylomicrons and VLDL to HDL 26 and cholesteryl ester transfer protein 
(CETP), which can exchange CE from HDL with TG from apoB-containing lipoproteins 27. 
When CE is transferred from HDL to apoB containing lipoproteins, a more atherogenic profile 
is created with low levels of HDL cholesterol and high levels of LDL cholesterol 28. 
Lipolysis of lipoproteins
Lipoprotein lipase (LPL) is the main enzyme responsible for lipolysis of chylomicron 
and VLDL TG into glycerol and FA. LPL hydrolyses the ester bonds of mono-, di-, and 
triglycerides. After TG depletion, the resulting chylomicron remnants are taken up by the 
liver mainly via apoE specific recognition sites such as the LDL receptor (LDLr) and the 
LDLr related protein (LRP)29, 30. IDL and LDL particles, formed after lipolysis of VLDL 
particles, can also be cleared by the LDLr via apoE. In addition, LDL particles can be 
taken up by extra-hepatic tissues that need the cholesterol from LDL for proper cellular 
functioning and steroid hormone synthesis 22. 
LPL is expressed in almost all tissues, though most abundantly in tissues that utilize FA 
for energy (e.g. heart and skeletal muscle) or storage (adipose tissue) 22. LPL is not expressed 
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in adult livers. LPL is formed in parenchymal cells and translocated to the luminal surface 
of endothelial cells to which it becomes anchored to interact with TG-rich lipoproteins 31. 
Regulation of LPL is tissue-specific and dependent on nutritional status. Adipose tissue LPL 
activity is high in the postprandial state, since in this state FA are primarily used for storage. 
In contrast, during fasting when FA are needed as an energy source, heart and muscle LPL 
activity is high 32. The activity of LPL is also influenced by apolipoproteins. They can either 
stimulate LPL activity (e.g. apoCII and apoAV) 33 34, or inhibit the activity (e.g. apoCIII and 
apoCI) 35 36, thereby influencing plasma TG and FA levels. 
Mouse models with tissue specific deletion or over expression of LPL have indicated 
an important role for LPL in the metabolic syndrome. For instance, LPL over expression in 
muscle has been associated with increased TG storage in the muscle 37 38, 39, reduced high 
fat diet (HFD)-induced obesity 37 and may affect insulin sensitivity 38, 39. Deletion of LPL 
in adipose tissue reduced bodyweight in a genetically obese mouse model 40. Modifiers of 
LPL action play a role in the development of the metabolic syndrome as well. For example, 
mice that lack the LPL inhibitor apoCIII are more obese and develop more severe insulin 
resistance after HFD feeding 41, whereas genetically obese mice that over express the LPL 
inhibitor apoCI are less obese and less insulin resistant than control genetically obese 
mice 42. Overexpression of apoAV, a stimulator of LPL, however did not affect obesity or 
insulin resistance development in mice subjected to a HFD 43. 
Cellular uptake of fatty acids
Uptake, transport and storage of TG-derived FA into tissues are highly regulated since 
unbound FA are cytotoxic. FA have been shown to passively transfer across cell membranes, 
however several fatty acid binding proteins exist to facilitate the cellular entry of FA. CD36, 
also called FA translocase, is such an important fatty acid binding protein that facilitates 
FA uptake. CD36 is an 88 kDa integral membrane protein and is expressed in many tissues, 
including adipose tissue, heart, skeletal muscle and intestine 44, but also in endothelial cells, 
platelets and macrophages 45. In liver, CD36 is not a main fatty acid transporter 44. In addition 
to its role in facilitating FA transport, CD36 can also function as class B scavenger receptor 46. 
As scavenger receptor, CD36 plays a central role in development of different metabolic 
abnormalities associated with the metabolic syndrome such as hypertriglyceridemia, 
atherosclerosis, inflammation and insulin resistance 47. CD36-deficient mice are protected 
against HFD-induced obesity 48, 49 and this thesis. However, studies investigating the effects of variants 
in the CD36 gene on obesity in humans have yielded conflicting results. Choquet et al. found no 
effect of CD36 single nucleotide polymorphisms (SNPs) on onset of obesity 50, whereas Heni et 
al. found other SNPs that were associated with waist circumference and BMI 51. Whether CD36-
deficiency protects against insulin resistance is controversial. CD36-deficient mice are insulin 
resistant in the liver, but remain insulin sensitive in muscle 52. In a specific CD36-deficient 
Japanese population insulin sensitivity was decreased 53, 54, although another study did not find 
an effect on insulin sensitivity in similar CD36-deficient subjects 55. In addition some SNPs in 














Intracellular processing of fatty acids
Inside the cell, diacylglycerol acyltransferases (DGATs) catalyze the re-esterification of FA 
that are not utilized for energy, so that they can be stored as TG intracellular 59. In the fed 
state, adipose tissue is the main site for TG storage. In the adipose tissue there is a continuous 
cycle of lipolysis and re-esterifcation of FA that is regulated by several enzymes. Adipose 
triglyceride lipase (ATGL) catalyzes the first step in TG lipolysis: the breakdown of TG into 
diacylglycerol (DG) and FA. Hormone sensitive lipase (HSL) catalyzes the breakdown of DG 
into monoacylglycerol (MG) and FA. In the fed state, HSL activity is inhibited by insulin 
resulting in intracellular net uptake of FA and accumulation of TG in adipose tissue. During 
fasting or enhanced energy demand hormones such as glucagon stimulate HSL activity, 
which results in the release of FA into the circulation. The released FA can be taken up by 
other tissues and used as energy source 60. Interestingly, decreased ATGL and HSL mRNA 
and protein levels have been reported in obese individuals with insulin resistance 61 62.
Role of fatty acids in the pathology of insulin resistance 
The increased prevalence of the metabolic syndrome in our society is driven by an increasing 
disbalance between energy intake and energy expenditure. The expanded adipose tissue mass 
that is characteristic of obesity is thought to play an important role in the pathology of the 
metabolic syndrome. Adipose tissue continuously takes up and secretes FA in a so called 
futile cycle as discussed in the previous paragraph. Under normal, healthy conditions, the net 
balance of absorption and secretion is tightly regulated. The absolute amount of the adipose 
tissue determines the contribution to the futile cycle. With increasing adipose tissue mass, the 
contribution of the futile cycle to basal plasma FA levels will increase and it has been hypothesized 
that this increase in cytotoxic FA is one of the causes driving the metabolic syndrome.
The lipid overload at the onset of HFD-induced obesity has been related to the onset 
of insulin resistance. In mice and humans, intravenous lipid infusions cause insulin 
resistance 63-65. Excess lipids may be delivered to non-adipose tissues (ectopic fat deposition) 
that are not suited for fat storage (i.e. skeletal muscle and the liver), thereby increasing 
the formation of specific fatty acid metabolites such as fatty acyl CoA, diacylglycerol, and 
ceramides that may directly impair insulin signaling. Normally, insulin stimulates tyrosine 
phosphorylation of insulin receptor substrate (IRS) proteins that mediate insulin signaling. 
In insulin resistance, serine residues of IRS are phosphorylated instead, which interferes in 
insulin receptor signaling 66. In mice and humans it was found that increased intramyocellular 
diacylglycerol activates protein kinase C isoforms, which can inhibit insulin signaling by 
phosphorylating serine residues of IRS-1 67, 68. Moreover, increased ceramide levels in plasma 
and muscle of mice and human also inhibit insulin signaling 69 70, 71. In addition to ectopic fat 
deposition, high levels of FA can also lead to metabolic inflammation, another key event that 
can impair insulin signaling which will be further discussed in the following paragraphs. 
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Classically, inflammation is described as the primary response of the body against injury. This 
classical response is strong, acute and limited. In contrast to this acute inflammatory response, 
it has been discovered in the past decades that many obese subjects have slightly increased levels 
of inflammatory markers in plasma, which remain elevated over a longer period of time. This 
kind of inflammation is referred to as low-grade-, chronic- or metabolic inflammation, since it 
is hypothesized that this inflammation is triggered by a surplus of nutrients 72. 
The immune response consists of 2 branches, the innate response that is relatively non-
specific and the adaptive response, which is specific. Leukocytes such as macrophages and 
mast cells are the main cells of the innate immune system. T- and B-lymphocytes are the main 
cells of the adaptive immune system. T-lymphocytes have diverse roles. CD4 T-lymphocytes 
activate other cells of the immune system such as B-lymphocytes and macrophages. CD8 
T-lymphocytes are cytotoxic and kill cells that are infected with pathogens. The primary 
function of B-lymphocytes is to produce antibodies that can bind to pathogens so that 
they become tagged for destruction. Both the innate and the adaptive arms of the immune 
response are involved in metabolic inflammation 73-76. In the following sections adipose 
tissue inflammation and the role of different immune cells herein is described. A schematic 
overview is depicted in Figure 2. In addition, the role of metabolic inflammation in the 
pathology of insulin resistance is discussed. 
Adipose tissue inflammation
This section specifically focuses on the role of immune cells that reside in adipose tissue. 
Nowadays, adipose tissue is no longer regarded as a simple depot for excess calories. 
Adipose tissue secretes hormones such as leptin and adiponectin, acute-phase proteins, 
cytokines, chemokines, growth factors and components of the complement system 77. 
These peptides all influence insulin sensitivity and inflammation. Normally the liver 
and the lymphoid organs are the main production sites of inflammatory mediators, but 
when adipose tissue expands, adipose tissue also becomes an important producer of these 
inflammatory mediators 78. Besides secretion of pro inflammatory molecules, obese adipose 
tissue contains more immune cells such as macrophages 79, T-lymphocytes 80 and activated 
B-lymphocytes 81. Finally, hypertrophic adipocytes secrete more FA, which can have a pro 
inflammatory effect via Toll Like Receptor (TLR) 2 or 4. All these aspects contribute to the 
pro inflammatory phenotype that is highly prevalent in obese subjects. 
Role of macrophages in adipose tissue inflammation
When there is a surplus of nutrients, adipose tissue needs to expand to increase its storage 
capacity. Adipocyte hyperplasia (increase in adipocyte number) and adipocyte hypertrophy 
(increase in adipocyte size) can contribute to this process 82. The process of adipose tissue 















blood vessel formation, since expansion of adipose tissue is physically limited by nutrient and 
oxygen supply. Lack of nutrients and oxygen result in hypoxia, adipocyte stress and adipocyte 
cell death, which are characterized by enhanced chemokine secretion and deregulation of 
FA fluxes. These processes at the onset of adipose tissue expansion can lead to increased 
macrophage recruitment within adipose tissue. Indeed, macrophages are increased in obese 
adipose tissue 73. These adipose tissue macrophages (ATMs) are not a uniform population 
of cells, but can exhibit a range of activation states. ATMs that reside in lean adipose tissue 
are predominately alternatively activated macrophages (M2 macrophages). Alternative 
activation of macrophages occurs in response to IL-4 and IL-13 and promotes tissue repair 
and remodeling. Alternative activated macrophages are anti-inflammatory and secrete 
the anti-inflammatory cytokine IL-10. In contrast, in obese adipose tissue, macrophages 
are more polarized towards classical activated macrophages (M1 macrophages). Classical 
activation occurs in response to IFN-γ and results in pro inflammatory macrophages that 
Figure 2. Schematic overview of adipose tissue inflammation. Over nutrition induces an 
accumulation of B-lymphocytes in adipose tissue. B-lymphocytes are able to interact with 
T-lymphocytes, which results in the production of IgG autoantibodies. These antibodies may 
promote complement activation and Fc receptor cross-linking on macrophages and mast cells, 
which contributes to enhanced adipose tissue inflammation, with subsequent impairment of 
adipocyte functions (Adapted from Mallat, Nature Medicine 2011). 
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secrete e.g. IL-6 and TNF-α 83. These pro inflammatory cytokines can act on adipocytes to 
induce insulin resistance (this is further discussed in the section on the role of metabolic 
inflammation in the pathology of insulin resistance).
Cytokines produced by ATMs can have endocrine cross talk with skeletal muscle and 
liver; two other organs that have increased macrophage content in obese patients and thus 
can also develop inflammation-driven insulin resistance 84 85. 
Role of T-lymphocytes in adipose tissue inflammation
In addition to macrophages, other immune cells like T-lymphocytes are also increased 
in obese adipose tissue 86. Two main populations of T-lymphocytes exist: T-helper 
lymphocytes, expressing co-receptor CD4 and cytotoxic T-lymphocytes, expressing 
co-receptor CD8. T-helper lymphocytes are important for the development of an antigen-
specific B-lymphocyte response (which will be discussed in the following paragraph). The 
population of T-helper lymphocytes can roughly be subdivided into pro inflammatory cells 
(TH1, TH17) and anti-inflammatory and regulatory sublineages (TH2, Foxp3
+). In obese 
subjects the number of TH1 and CD8
+ T-lymphoyctes in adipose tissues is increased, whereas 
the number of regulatory T-lymphocytes is decreased. Recent studies have suggested that 
TH1 lymphocytes and CD8
+ T-lymphocytes help recruit macrophages into adipose tissue 
and stimulate the M1 macrophage inflammatory activation status. It is speculated that these 
lymphocytes respond to unique antigens that are generated in obese adipose tissue during 
HFD feeding. Gain- and loss-of-function studies have indicated that these TH1 and CD8
+ 
T- lymphocytes are associated with increased insulin resistance 76, 87. 
Role B-lymphocytes in adipose tissue inflammation
B-lymphocytes are also recruited to adipose tissue shortly after initiation of HFD 86 and 
activation of B-lymphocytes is increased in patients with type 2 diabetes 81. B-lymphocytes 
produce antibodies, also named immunoglobulins (Ig) in response to antigens. These 
antibodies have a so-called constant part (Fc region) that can bind to C1q, which is the 
recognition component of the classical complement pathway. Upon binding to C1q, the 
complement system is activated and processes such as phagocytosis are initiated to clear 
pathogens 88, 89. The Fc region can also bind to Fc receptors (FcRs). FcRs can be found on 
most hematopoietic cells, such as neutrophils, natural killer cells, dendritic cells, mast cells 
and monocytes/macrophages 90. Upon binding to FcRs, a range of cellular responses is 
initiated, such as phagocytosis, antigen-dependent cellular cytotoxicity and secretion of 
cytokines 91. FcRs and the complement system thus form a link between the innate and the 
adaptive immune system. FcRs are multi-subunit receptors, in which the ligand-binding 
α-chain associates with the signal transducing γ-chain that contains an immunoreceptor 
tyrosine-based motif (ITAM). In addition to signaling, the γ-chain is also essential for 
normal surface expression of FcαRI, FcγRI and III and FcεRI. 
Recently, it has been shown that B-lymphocytes from HFD-fed mice can activate CD8+ 














pro inflammatory cytokines such as INF-γ that stimulate M1 macrophage polarization, 
which can eventually lead to insulin resistance. The requirement of T-lymphocytes in this 
process suggests that the antigen presenting function of B-lymphocytes is important for the 
development of insulin resistance. In line with this idea, it was found that B-lymphocytes 
from HFD-fed mice produce IgG antibodies that via their Fc portion elicit a pro inflammatory 
cytokine response. It is possible that the source of the antigens responsible for the detrimental 
effect on insulin sensitivity is formed by stressed apoptotic adipocytes, since IgG antibodies 
concentrate in so called crown-like structures within adipose tissue. Crown-like structures 
are composed of dead adipocytes surrounded by activated adipose tissue macrophages. 
Antibodies produced by B-lymphocytes are thus important for the development of 
HFD-induced insulin resistance, however the role of antibody effector pathways in this 
process is not clear yet 75. 
The role of metabolic inflammation in the pathology of insulin resistance
Thus, in addition to FA and their metabolites as discussed above, tissue specific and systemic 
inflammatory signals likely play determinant roles in the pathology of insulin resistance. 
TNF-α, IL-6 and IL-1β secreted by classical activated macrophages can activate Jun 
N-terminal kinase (JNK) and inhibitor of κB kinase (IKKB) in adipocytes, myocytes and 
hepatocytes. Like FA metabolites, these kinases are able to phosphorylate the serine residue 
of IRS, thereby inhibiting insulin signaling 92 93 94. Besides acting on IRS, these kinases also 
activate transcription factor activator protein 1 (AP1) (c-Jun/Fos) and nuclear factor NF-κB, 
which induces further inflammatory gene expression 95. Mouse models that lack either JNK1 
or IKKB in myeloid cells are protected against obesity-induced insulin resistance 96 84. 
Saturated FA may also have a direct pro inflammatory effect. Innate immune cells possess 
recognition receptors that sense invading pathogens and subsequently start to stimulate pro 
inflammatory signaling pathways in order to recruit other immune cells. TLRs form such 
a family of recognition receptors. Recently it has been found that in addition to pathogens, 
saturated FA can also interact with TLR4 and TLR2 and activate pro inflammatory signaling 
pathways 64, 97. Accordingly, TLR4 and TLR2 deficient mice have reduced HFD-induced 
inflammation, as well as reduced HFD-induced insulin resistance 64, 98, 99. In addition to TLRs, 
the inflammasome, a multiprotein complex consisting of a member of the Nod-like receptor 
family (e.g. NLRP3), and the inflammasome adaptor molecule ASC, can also recognize 
pathogens. When the inflammasome becomes activated, caspase-1 is recruited and activated 
which results in activation of the pro inflammatory cytokines IL-1β and IL-18 100, 101. Recently, 
it was discovered that HFD feeding results in activation of caspase-1 in adipose tissue of mice. 
In these HFD-fed mice increased IL-1β and IL-18 protein levels were observed 102. In line with 
these results caspase-1 deficient mice demonstrated reduced HFD-obesity, HFD-induced-
insulin resistance and HFD-induced inflammation in adipose tissue 103. 
17
The research described in this thesis focuses on TG/FA metabolism and inflammation, 
two key processes that are deranged during the development of the metabolic syndrome. 
We specifically focus on insulin resistance, an important metabolic abnormality of the 
metabolic syndrome. In Chapter 2 we studied obesity development, fat deposition, 
adipocyte development and functioning and insulin sensitivity in a murine model deficient 
for a major FA transporter, CD36. Mice deficient in CD36 have increased fasting plasma 
FA, TG and total cholesterol levels and decreased fasting plasma glucose levels on normal 
chow diet 104, indicating a role for CD36 in lipoprotein, FA and glucose metabolism. Because 
CD36 facilitates FA uptake and FA uptake is important in adipogenesis, the CD36-/- mice 
is an appropriate model to study fat deposition, adipocyte development and functioning 
and its effect on insulin sensitivity. In Chapter 3 and 4 we determined how different 
pharmacological interventions in inflammation affect lipid metabolism (Chapter 3) or 
insulin sensitivity (Chapter 4). In Chapter 3 we investigated the mechanism of TG lowering 
by the non-steroidal anti-inflammatory drug aspirin. Human apolipoprotein CI-expressing 
mice (APOC1) were used as a model for hypertriglyceridemia. APOC1 mice have increased 
plasma TG due to diminished clearance of VLDL particles through apoCI-mediated 
inhibition of LPL. In Chapter 4 we investigated whether an anti-inflammatory compound 
derived from an extract of Humulus lupulus L., META060, had the capacity to improve 
insulin sensitivity in a HFD fed mouse. In Chapter 5 we investigated a novel mechanism 
underlying the inflammation that is associated with the metabolic syndrome. We used 
the FcR γ-chain-/- mice, characterized by diminished activation of IgG and IgE antibody 
effector pathways, to study the role of functional FcRs in the development of obesity-
induced insulin resistance. It has been discovered that HFD-induced IgG play a role in the 
development of insulin resistance. However, the role of functional FcRs in this process has 
not been investigated yet. The last chapter provides an overall discussion and conclusion 
about this PhD project (Chapter 6).
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CD36 IS IMPORTANT FOR ADIPOCYTE 
RECRUITMENT AND AFFECTS LIPOLYSIS 
ABSTRACT
Objective: The scavenger receptor CD36 facilitates the cellular uptake of long chain fatty 
acids. Since CD36-deficiency attenuates the development of high fat diet (HFD)-induced 
obesity, we set out to characterize the role of CD36-deficiency in preadipocyte recruitment 
and adipocyte function. 
Design and methods: Fat cell size and number were determined in gonadal, visceral and 
subcutaneous adipose tissue of CD36-/- and WT mice after six weeks on HFD. Basal lipolysis 
and insulin-inhibited lipolysis were investigated in gonadal adipose tissue.
Results: CD36-/- mice showed a reduction in adipocyte size in all fat pads. Gonadal adipose 
tissue also showed a lower total number of adipocytes due to a lower number of very small 
adipocytes (diameter <50 µm). This was accompanied by an increased pool of preadipocytes 
which suggests that CD36-deficiency reduces the capacity of preadipocytes to become 
adipocytes. Regarding lipolysis, in adipose tissue from CD36-/- mice cAMP levels were 
increased and both basal and 8-bromo-cAMP stimulated lipolysis were higher. However, 
insulin-mediated inhibition of lipolysis was more potent in CD36-/- mice. 
Conclusions: These results indicate that during fat depot expansion, CD36-deficiency 
negatively affects preadipocyte recruitment and that in mature adipocytes, CD36-deficiency 














2Obesity, and in particular abdominal obesity, is associated with several metabolic 
abnormalities such as insulin resistance and hypertriglyceridemia, which increase the risk of 
developing type 2 diabetes and eventually cardiovascular morbidity and mortality 1. Obesity 
is caused by a chronic positive energy balance that increases the storage of triglycerides (TG) 
in adipose tissue. This storage of energy is partly regulated by fatty acid (FA) transporter 
proteins in adipocytes, which facilitate the cellular entry of lipoprotein derived FA. One 
of these FA transporters is CD36 2, 3, a 88 kDa glycoprotein (reviewed in 4) that primarily 
facilitates the transport of long chain FA. The role of CD36 in white adipose tissue (WAT) 
is illustrated by diminished uptake of the FA analogs BMIPP and IPPA in adipose tissue 
of CD36-deficient (CD36-/-) mice fed a chow diet 5. Other studies have demonstrated 
that CD36-deficiency protects against obesity induced by a high fat diet (HFD) 6, 7 and 
development of cardiometabolic problems 8. 
Since CD36-deficiency attenuates the development of HFD-induced obesity, we were 
interested in the role of CD36 in adipocyte development and function. We investigated 
adipocyte cell size and number in various adipose tissue depots to determine whether 
CD36-deficiency affects adipocyte hypertrophia (i.e adipocyte growth) and/or hyperplasia 
(i.e. recruitment of new adipocytes), as both these parameters determine the expansion 
capacity of adipose tissue. Moreover, we determined the intra cellular lipid accumulation 
of isolated preadipocytes of CD36-/- versus wild-type (WT) mice in vitro after incubation in 
adipogenic media. In addition, lipolysis rate of isolated mature adipocytes of CD36-deficient 
mice versus WT mice was determined, since adipocyte volume is not only determined by 
uptake of FA which lead to TG storage, but also by the level of FA release during the process 
of adipocyte lipolysis. Taken together, we aimed to investigate the role of CD36 in adipocyte 
development and function, since CD36 is involved in development of diet-induced obesity. 
The current study shows that CD36 affects both adipocyte recruitment and lipolysis.
2.1 INTRODUCTION
2.2 MATERIALS AND METHODS
Animals
The generation of CD36-/- mice has been described previously 9. For this study, CD36-/- mice 
were crossed back eight times to the C57Bl/6J background. CD36-/- mice were bred at the 
Leiden University Medical Center, Leiden, The Netherlands. WT control mice (C57Bl/6J 
background) were purchased from Charles River (Maastricht, The Netherlands). The mice 
used in experiments were males, housed under standard conditions with free access to 
water and food. Mice were fed a HFD (45% energy derived from lard fat; D12451, Research 
Diet Services, Wijk bij Duurstede, The Netherlands) when they were 12 weeks of age to 
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induce obesity. Body weight was measured regularly. All experiments were approved by the 
animal ethics committee of Leiden University Medical Center.
Body composition 
After 11 weeks of HFD feeding body composition was determined in overnight fasted mice 
using dual energy X-ray absorptiometry (DEXA) (Norland Stratec Medizintechnik GmbH, 
Birkenfeld, Germany).
Generation of TG-rich emulsion particles
VLDL-like TG-rich emulsion particles were prepared and characterized as described 
previously 10. Lipids (100 mg) at a weight ratio of triolein: egg yolk phosphatidylcholine: 
lysophosphatidylcholine: cholesteryl oleate: cholesterol of 70: 22.7: 2.3: 3.0: 2.0, supplemented 
with 100 µCi of glycerol tri[9,10(n)-3H]oleate ([3H]TO) (GE Healthcare, Little Chalfont, UK) 
were sonicated at 10 µm output using a Soniprep 150 (MSE Scientific Instruments, Crawley, 
UK). Density gradient ultracentrifugation was used to obtain 80 nm-sized emulsion 
particles, which were used for subsequent experiments. TG content of the emulsions was 
measured using a commercially available kit (Roche Molecular Biochemicals, Indianapolis, 
IN). Emulsions were stored at 4°C under argon and used within 7 days.
In vivo clearance of TG-rich emulsion particles
To study the in vivo clearance of the VLDL-like emulsion particles, mice were fed a HFD for 
13 weeks. Mice were fasted 4 h (from 8.00 am to 12.00 pm) prior to the start of the experiment 
and anesthetized by intraperitoneal injection of acepromazine (6.25 mg/kg Neurotranq, 
Alfasan International BV, Weesp, The Netherlands), midazolam (6.25 mg/kg Dormicum, Roche 
Diagnostics, Mijdrecht, The Netherlands), and fentanyl (0.31 mg/kg Janssen Pharmaceuticals, 
Tilburg, The Netherlands). Subsequently, mice were injected (t=0) intravenously with 200 µL of 
[3H]TO-labeled emulsion particles at a dose of 1 mg of TG per mouse. Blood samples were taken 
from the tail at 2, 5, 10, 20 and 30 minutes after injection and plasma 3H-activity was counted. 
Plasma volumes in ml were calculated as 0.04706 x body weight (g) as determined from 125I-BSA 
clearance studies as described previously 11. After taking the last blood sample, the liver, heart, 
spleen, quadriceps, brown adipose tissue and white adipose tissue (i.e. gonadal, visceral and 
subcutaneous) were collected. Organs were dissolved overnight at 60°C in Tissue Solubilizer 
(Amersham Biosciences, Rosendaal, The Netherlands) and 3H-activity was counted. Uptake of 
[3H]TO-derived radioactivity by the organs was calculated from the 3H activity in each organ 
divided by plasma-specific activity of [3H]TG and expressed per mg wet tissue weight. Values 
were corrected for plasma radioactivity present in the respective tissues 12.
Liver lipids
Lipids were extracted from livers of WT and CD36-/- mice fed a HFD for 11 weeks according 
to a modified protocol from Bligh and Dyer 13. Briefly, small liver pieces were homogenized 















chloroform: methanol (3:1 v/v) to 45 μL homogenate. The chloroform phase was dried and 
dissolved in 2% Triton X-100. Hepatic TG and total cholesterol (TC) concentrations were 
measured using commercial kits (11488872 and 236691, Roche Molecular Biochemicals, 
Indianapolis, IN, respectively). 
Hepatic phospholipid (PL) concentrations were measured using the commercial 
available kit phospholipids B (Wako Chemicals GmbH, Neuss, Germany). Liver lipids were 
expressed per mg protein, which was determined using the BCA protein assay kit (Pierce).
Determination of adipocyte size, adipocyte lipolysis and preadipocyte 
differentiation capacity
To measure adipocyte size, mice were fed a HFD for 6 weeks and sacrificed. Gonadal, visceral 
and subcutaneous fat pads were removed and kept in PBS. It was decided to perform the 
adipocyte morphology and functionality experiments at the week 6 time point to be sure that 
metabolic adaptions to a HFD were still occurring in the animals and a new set-point had not 
yet been reached. The tissue was minced and digested in 0.5g/l collagenase in HEPES buffer 
(pH 7.4) with 20 g/l of dialyzed bovine serum albumin (BSA, fraction V, Sigma, ST Louis, USA) 
for 1 h at 37oC. The disaggregated adipose tissue was filtered through a nylon mesh with a pore 
size of 236 mm. For the isolation of mature adipocytes, cells were obtained from the surface of 
the filtrate and washed several times. Cell size was determined using an imaging processing 
technique implemented in MATLAB which automatically determines adipocyte sizes of 
hundreds of adipocytes from microscopic pictures of isolated adipocytes (~1000 cells/fat tissue 
sample). A manuscript describing the method is under preparation. From the measured cells 
the adipocyte size distribution, mean adipocyte diameter and adipocyte number per fat pad 
were determined. Also the volume-weighted mean adipocyte diameter was calculated, which 
is a measure of the mean adipocyte diameter corrected for the amount of fat that an adipocyte 
can store 14. In addition, the anti-lipolytic effect of insulin was determined in the adipocytes by 
incubating them for 2 h at 37oC in DMEM/F12 with 2% BSA in combination with or without 
8-bromoadenosine 3’-5’-cyclic monophosphate (8b-cAMP) (10-3M) (Sigma) and/or insulin 
(10-11M,10-9M and 10-7M). Glycerol concentrations (index of lipolysis) were determined using 
a commercially available free glycerol kit (Sigma) with the inclusion of the hydrogen peroxide 
sensitive fluorescence dye Amplex Ultra Red, as described by Clark et al. 15. 
For the isolation of preadipocytes, the infranatant of the adipose tissue filtrate was 
centrifuged at 200 x g for 10 min at room temperature and treated with erythrocyte lysis 
buffer. The cells were washed 2 times, re-suspended in DMEM/NUT.MIX.F12 medium and 
supplemented with 10% fetal calf serum (FCS) and 100 mg/ml penicillin-streptomycin and 
inoculated into 96-well plates (6 wells/adipose tissue region) at a density of 30 000 cells/
ml and kept at 37oC, in 5% CO2. The cells were expanded until confluency after which 
adipocyte differentiation was induced using an adipogenic medium containing DMEM/F12 
with dexamethasone 0.1µM, 3-isobutyl-1-methylxanthine (IBMX) 25µM, insulin 17 nM, 
indomethacin 60µM, 10% FCS and 100 mg/ml penicillin-streptomycin. After 4 days medium 
was changed to maintenance medium containing insulin 17 nM and 10% FCS. After 1 more 
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day the cells were lipid filled and intra cellular lipid accumulation was determined using a 
fluorometer after incubating the cells with Nile Red (Sigma-Aldrich, St. Louis, MO).
Adipose tissue cyclic AMP level, RNA isolation and qPCR analysis
Adenosine 3’-5’-cyclic monophosphate (cyclic AMP, cAMP) levels were determined in gonadal 
fat samples of mice fed a HFD for 6 weeks using the cAMP direct immunoassay kit from 
Biovision (Biovision, Inc, Milpitas, CA) according to the instructions of the manufacturer. 
RNA from gonadal fat of mice was isolated using the Nucleospin RNA /Protein kit (Macherey-
Nagel, Düren, Germany) according to the instructions of the manufacturer. The quality of 
each mRNA sample was examined by lab-on-a-chip technology using Experion Stdsens 
analysis kit (Biorad, Hercules, CA). 600 ng of total RNA was reverse-transcribed with iScript 
cDNA synthesis kit (Bio-Rad) and obtained cDNA was purified with Nucleospin Extract II kit 
(Macherey-Nagel). Real-Time PCR was carried out on the IQ5 PCR machine (Biorad) using 
the Sensimix SYBR Green RT-PCR mix (Quantace, London, UK) and QuantiTect SYBR Green 
RT-PCR mix (Qiagen). mRNA levels were normalized to mRNA levels of glyceraldehyde-3-
phosphate dehydrogenase (Gapdh). Primer sequences are listed in table 1. 
Hyperinsulinemic euglycemic clamp analysis
To assess insulin sensitivity mice were fed a HFD for 11 weeks. Hyperinsulinemic 
euglycemic clamps were performed as described earlier 16. Briefly, after an overnight fast, 
animals were anesthetized as described above and an infusion needle was placed in the 
tail vein. Basal glucose parameters were determined during a 60-min period, by infusion 
of D-[3-3H]glucose to achieve steady-state levels. A bolus of insulin (3 mU) was given and 
Table 1. Primers used for quantitative real-time PCR analysis.
Gene Forward primer Reverse primer
F4/80 CTTTGGCTATGGGCTTCCAGTC GCAAGGAGGACAGAGTTTATCGTG
MRC-1 GAGAGCCAAGCCATGAGAAC GTCTGCACCCTCCGGTACTA
MCP-1 GCA TCT GCC CTA AGG TCT TCA TTC ACT GTC ACA CTG GTC ACT CCT A
IL-6 ACCACGGCCTTCCCTACTTC CTCATTTCCACGATTTCCCAG 






F4/80, marker for macrophages; MRC-1, mannose receptor 1; MCP-1, monocyte chemotactic 
protein-1; IL-6, interleukin-6; IL-10, interleukin-10; HSL, hormone sensitive lipase; ATGL, adipose 
















a hyperinsulinemic euglycemic clamp was started with a continuous infusion of insulin 
(5 mU/h) and D-[3-3H]glucose and a variable infusion of 12.5% D-glucose (in PBS) to 
maintain blood glucose levels at euglycemic levels. Blood samples were taken every 5-10 
min from the tip of the tail to monitor plasma glucose levels (AccuCheck). Seventy, eighty 
and ninety minutes (steady-state) after the start of the clamp, blood samples (70 μl) were 
taken for determination of plasma glucose and insulin using commercially available kits 
(Instruchemie and Crystal Chem Inc). Turnover rates of glucose (μmol/min/kg) were 
calculated during the basal period and in steady-state clamp conditions as the rate of tracer 
infusion (dpm/min) divided by the plasma-specific activity of 3H-glucose (dpm/μmol). All 
metabolic parameters were expressed per kilogram of body weight. The hepatic glucose 
production (EGP) is calculated from the rate of disappearance (Rd) and glucose infusion 
rate (GIR) by the following equation: Rd = EGP + GIR. The Rd is measured from Steele’s 
equation in steady state using the tracer infusion rate (Vin) and plasma-specific activity 
(SA) of 3H-glucose (dpm/μmol) by the following formula: Rd = Vin/SA. 
Statistical analysis
Data are presented as means ± SD. Statistical differences were calculated using the 
nonparametric Mann-Whitney test or two-way-ANOVA (SPSS 16, SPSS Inc, Chicago, IL). 
A P-value < 0.05 was regarded statistically significant. 
2.3 RESULTS
CD36-deficiency reduces high fat diet-induced obesity 
To induce obesity, male CD36-/- and WT mice were fed a HFD containing 45 energy% fat for 
12 weeks, and body weight of the mice was followed during the HFD intervention. CD36-/- 
mice gained less body weight than WT mice (Fig. 1A). After 11 weeks, body composition was 
determined by DEXA analysis. As compared to WT mice, lean body mass was similar, but 
total body fat was 36% lower in CD36-/- mice (5.8 ± 1.6 versus 9.0 ± 3.1 g; P<0.05) (Fig. 1B). 
In line with this observation, weights of isolated fat pads were lower in CD36-/- mice (gonadal 
fat -38%; P<0.01, visceral fat -35%; P<0.01, subcutaneous fat -31%; P<0.05) (Fig. 1C). When 
mice were fed a HFD for 6 weeks, similar differences in phenotype between WT and CD36-/- 
mice were observed. Fat pad weights of CD36-/- mice were significantly lower after 6 weeks of 
HFD (gonadal fat -48%; P<0.001, visceral fat -33%; P<0.01, subcutaneous fat -41%; P<0.001), 
while liver weight was significantly higher (data not shown). 
CD36-deficiency decreases uptake of TG-rich particle derived FA by white 
adipose tissue
To confirm that CD36-deficiency affects the tissue-specific uptake of FA that are derived from 
TG-rich particles, the plasma clearance and organ distribution of [3H]TO-labeled TG-rich 
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VLDL-like emulsion particles was evaluated in HFD-fed CD36-/- mice versus WT mice. CD36-
deficiency did not affect the plasma half-life of [3H]TO (t½ = 5.0±1.7 versus 6.0±1.3 min) 
(Fig. 2A). These results indicate that CD36-/- mice have equal capacity to clear TG-derived FA 
from plasma. However tissue-distribution of these FA was different for the two mouse strains. 
CD36-deficiency significantly decreased the uptake of [3H]TO-derived activity in the heart 
(-38%; P<0.001), gonadal fat (-29%; P<0.01) and visceral fat (-30%; P<0.01), while the uptake of 
[3H]TO-derived activity in the liver (+42%; P<0.01) and spleen (+49%; P<0.01) was significantly 
increased in the CD36-/- mice (Fig. 2B). These results imply that CD36-deficiency increases the 
flux of FA derived from TG-rich particles towards the liver, while decreasing the flux of FA 
Figure 1. CD36-deficiency reduces HFD-induced obesity. In a first set of mice, wild-type (WT) 
and CD36-deficient (CD36-/-) mice were fed a HFD for 12 weeks. Body weight of WT mice and 
CD36-/- mice was measured at the indicated time points (A). Values are means ± SD (n= 19-20 
per group); *P<0.05. In a second set of mice, after 11 weeks of HFD and after O/N fast, lean body 
mass and fat mass were determined by DEXA scan (B). Values are means ± SD (n= 7-11 per 
group); *P<0.05. In a third set of mice, after 12 weeks of HFD, tissues were dissected after a 4 h 
fast and weight of WT tissues and CD36-/- was determined (C). Values are means ± SD (n= 10 















towards the heart and WAT. Indeed, CD36-deficiency increased hepatic lipid content (+88%; 
P<0.001) (Fig. 2C), without affecting hepatic TC and PL levels (data not shown).
CD36-deficiency decreases adipocyte size in all fat pads and impairs 
adipocyte recruitment in gWAT
To investigate the effect of reduced FA uptake in adipose tissue on adipocyte morphology; 
adipocyte size distribution, volume-weighted mean adipocyte diameter and total adipocyte 
number were determined in isolated adipocytes from gonadal, visceral and subcutaneous 
fat pads from CD36-/- and WT mice fed a HFD for 6 weeks. In gonadal fat pads of CD36-/- 
mice less hypertrophic adipocytes (110-170 μM) were observed (Fig. 3A). For visceral and 
subcutaneous fat, the distribution was also shifted to the left. (Fig. 3B-C). Volume-weighted 
mean cell diameter was decreased in gonadal (-12%; P<0.001), visceral (-14%; P<0.01) 
Figure 2. CD36-deficiency decreases uptake of TG-rich particle derived FA by white adipose 
tissue. Wild-type (WT) and CD36-deficient (CD36-/-) mice were fed a HFD for 13 weeks. After 
a 4 h fast, mice received an intravenous injection of glycerol tri[3H]oleate-labeled VLDL-like 
emulsion particles (1.0 mg TG). At 2, 5, 10, 20 and 30 minutes after injection, blood samples 
were taken and 3H activities in plasma were counted and calculated as a percentage of the 
injected dose (ID) (A). Uptake of radioactivity by various organs of WT and CD36-/- mice was 
determined and presented as % of injected dose per gram wet weight (B). Values are means ± SD 
(n= 9); **P<0.01, ***P<0.001. BAT, Brown adipose tissue; WAT, white adipose tissue; g, gonadal; 
v, visceral; s, subcutaneous. In a second set of mice, after 12 weeks of HFD, liver TG content was 
determined and expressed per mg protein (C). Values are means ± SD (n= 10-11); ***P<0.001.
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and subcutaneous fat pads (-18%; P<0.001) of CD36-/- mice, indicating indeed smaller 
adipocytes (Fig. 3D). In gonadal fat, but not in visceral or subcutaneous fat a decreased 
number of total adipocytes was observed (-65%; P<0.001) (Fig. 3E). 
The number of adipocytes in adipose tissue is dependent upon the recruitment of 
preadipocytes out of the precursor pool that differentiate into adipocytes. The total number 
of cells in the stromal vascular fraction (SVF) (which includes the preadipocyte pool) was 
higher per gram of gonadal fat in CD36-/- mice (5.0 x 105 ± 3.3 x 105 versus 2.3 x 105 ± 5.3 x 104 
cells; P<0.01), indicating that the preadipocyte pool may be larger in gonadal fat of CD36-/- 
mice. In contrast, for visceral and subcutaneous fat no differences were observed in number 
of cells in the SVF (visceral: 1.0 x 106 ± 7.4 x 105 versus 8.0 x 105 ± 2.6 x 105 and subcutaneous: 
4.0 x 105 ± 3.0 x 105 versus 2.4 x 105 ± 8.2 x 104, respectively) (Fig. 3F). 
The SVF is a mixture of cell types where preadipocytes, leukocytes and endothelial cells 
constitute the major cell populations. mRNA expression of DLK1, a preadipocyte marker, 
tended to be higher in gonadal fat pads of CD36-/- mice (CD36-/- mice had a 44% higher 
DLK-1 expression; P=0.09), whereas expression of CD45, a leukocyte marker, was lower in 
CD36-/- mice (-39%; P<0.01), and CD31, an endothelial cell marker, was similar for CD36-/- 
and WT mice (Fig. 4A). These data indicate that the increased number of cells in the SVF 
may be accounted for by an increased number of preadipocytes, but not of leukocytes or 
endothelial cells. The number of very small adipocytes (diameter <50 µm) on the other 
hand, was much lower in the gonadal adipose tissue of CD36-/- mice (-65%; P<0.001) 
(Fig. 4B) which may indicate that less adipocytes are being recruited within gonadal fat 
pads of CD36-/- mice on a HFD, resulting in a higher pool of preadipocytes that remains in 
their SVF. This is illustrated in Fig. 3A by the bimodal cell size distribution in the gonadal 
fat of WT mice as opposed to the single peak in the cell size distribution in CD36-/- mice. 
CD36-deficiency does not affect preadipocyte intra cellular lipid accumulation 
To further study the underlying mechanisms which may explain the morphology of 
adipocytes in CD36-/- mice the intra cellular lipid accumulation in these cells was 
determined. This was assessed using isolated preadipocytes from CD36-/- and WT mice that 
were differentiated in an adipogenic medium. No differences were observed in intra cellular 
lipid accumulation between CD36-/- and WT mice for all fat pad regions (Fig. 5).
CD36-deficiency stimulates lipolysis but improves insulin-mediated 
inhibition of lipolysis
Morphology of adipocytes is not only determined by uptake of FA which leads to TG 
storage, but also by the level of FA release due to lipolysis. To investigate if CD36 plays 
a role in lipolysis, basal lipolysis was determined in isolated mature gonadal adipocytes 
of CD36-/- versus WT mice. Only gonadal adipocytes were studied because only from 
the gonadal fat pad the yield of adipocytes was enough to perform these experiments. 
CD36-/- mice had higher glycerol release both expressed per gram adipose tissue (data not 















Figure 3. CD36-deficiency decreases adipocyte size. Wild-type (WT) (solid line) and CD36-
deficient (CD36-/-) (dashed line) mice were fed a HFD for 6 weeks. Gonadal (gWAT), visceral 
(vWAT) and subcutaneous (sWAT) white adipose tissues were dissected. Adipocytes were 
isolated and adipocyte size distribution was determined (A-C). Values are means (n=9-10). 
Volume-weighted mean diameter (D) and total number of adipocytes were calculated (E). 
Stromal vascular fraction (SVF) was obtained and total number of cells in SVF of gWAT, vWAT 
and sWAT was determined (F). Values are means ± SD (n=9-10); **P<0.01, ***P<0.001.
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Figure 4. CD36-deficiency impairs adipocyte recruitment in gondal WAT. Wild-type (WT) and 
CD36-deficient (CD36-/-) mice were fed a HFD for 6 weeks. Gonadal white adipose tissue (gWAT) 
was dissected and mRNA levels of DLK-1, CD45 and CD31 in gWAT were determined (A). 
Values are means ± SD (n=10); **P<0.01. In addition, the % of very small adipocytes (<50μM) in 
gWAT was calculated (B). Values are means ± SD (n=9-10); ***P<0.001. 
Figure 5. CD36-deficiency does not affect preadipocyte lipid accumulation. Wild-type (WT) and 
CD36-deficient (CD36-/-) mice were fed a HFD for 6 weeks. Gonadal (gWAT), visceral (vWAT) 
and subcutaneous (sWAT) white adipose tissues were dissected and preadipocytes were isolated 
and differentiated in adipogenic medium. Lipid accumulation was determined with Nile Red. 
Values are means ± SD (n=9-10) (6 wells/adipose tissue region per mouse). 
and 8-bromo-cAMP (8b-cAMP) stimulated cells (2.1 fold, 2.8 fold respectively; P<0.05) 
(Fig. 6A). To test whether the increased lipolysis was due to higher levels of the lipolytic 
enzymes adipose triglyceride lipase (ATGL) and hormone sensitive lipase (HSL), mRNA 
expression of these enzymes was determined. However, both ATGL and HSL mRNA 
were lower in gonadal adipose tissue of CD36-/- versus WT mice (-27%; P<0.01 and -48%; 
P<0.001, respectively) (Fig. 6B). On the other hand, cAMP levels, which are reported to 
stimulate lipolysis, were increased in gonadal fat samples of CD36-/- mice (+31%; P<0.05) 
(Fig. 6C). Also the suppression of lipolysis by insulin was investigated in CD36-/- versus 
WT mice. Inhibition of lipolysis by 3 different insulin concentrations (10-11, 10-9, 10-7 M) 















already maximally suppressed lipolysis, since no further inhibition was found with insulin 
concentrations of 10-9 and 10-7 M (2 way ANOVA F=0.37; P=0.7). However inhibition of 
lipolysis was more potent in CD36-/- mice compared to WT mice (50% versus 29%; 2 way 
ANOVA F=10.65; P<0.01) (Fig. 6D). To investigate whether the increased adipocyte insulin 
sensitivity in lipolysis may be related to changes in adipose tissue inflammation, expression 
of inflammatory markers in gonadal adipose tissue was determined. As mentioned 
above, expression of CD45 was lower in CD36-/- mice. Moreover, a decreased expression 
of macrophage marker F4/80 (-29%; P<0.05) and a trend for higher IL-10 expression in 
gonadal adipose tissue of CD36-/- mice (+53%; P=0.08) (Fig. 6E) was observed. 
CD36-deficiency decreases hepatic insulin sensitivity
To investigate the effect of decreased adiposity and increased hepatic lipid content on 
metabolic abnormalities such as insulin resistance, we performed a hyperinsulinemic 
euglycemic clamp after an o/n fast. Glucose (5.4 ± 0.7 versus 5.4 ± 0.7 and 5.8 ± 0.6 versus 
5.6 ± 0.6 mM) and insulin levels (0.5 ± 0.2 versus 0.4 ± 0.2 and 4.0 ± 0.9 versus 4.5 ± 1.0 ng/mL) 
were equal for the 2 genotypes under basal as well as under hyperinsulinemic conditions. 
To maintain euglycemia during the insulin infusion, a similar amount of glucose was 
needed to be infused in CD36-/- mice compared to WT mice (GIR 25.7 ± 12.9 versus 
28.1 ± 5.9 μmol/min/kg) (Fig. 7A). The glucose disposal rates under basal conditions 
were higher for CD36-/- animals (32.3 ± 8.8 versus 25.1 ± 4.3 μmol/min/kg; P<0.05). 
During hyperinsulinemic conditions glucose disposal rates were similar for CD36-/- and 
WT animals (55.2 ± 19.9 versus 43.7 ± 4.6 μmol/min/kg), indicating that there was no 
difference in peripheral insulin sensitivity between CD36-/- mice compared to WT mice 
(Fig. 7B). Nevertheless, the CD36-/- mice developed aggravated hepatic insulin resistance 
compared to WT mice as indicated by the higher hepatic glucose production during the 
hyperinsulinemia (29.3 ± 11.3 versus 15.5 ± 3.6 μmol/min/kg; P<0.01) (Fig. 7C). 
2.4 DISCUSSION
The current study investigated the effects of CD36-deficiency on adipocyte morphology and 
functionality during HFD to get a better understanding of the role of CD36 in adipocytes. 
In accordance with others 6, 7, we found less adiposity in CD36-/- mice, which was due to 
a reduced uptake of FA in the adipose tissues. A decrease in fat pad mass can be caused by 
smaller adipocytes and/or by a decreased number of adipocytes. The CD36-/- mice showed less 
hypertrophy of their gonadal, visceral and subcutaneous adipocytes and the volume-weighted 
mean cell diameters of all fat pads studied were significantly lower in the CD36-/- mice. Thus 
the smaller fat pads in the CD36-/- are due to smaller fat cells in their adipose tissues. Moreover, 
for the gonadal adipose tissue, the CD36-/- mice showed a lower total number of adipocytes. 
The gonadal (but neither visceral nor subcutaneous) adipose tissue of CD36-/- mice had 
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Figure 6. CD36-deficiency stimulates 
lipolysis but improves insulin-
mediated inhibition of lipolysis. 
Wild-type (WT) and CD36-deficient 
(CD36-/-) mice were fed a HFD for 
6 weeks. Gonadal (gWAT) was 
dissected and adipocytes were 
isolated. Adipocytes were incubated 
for 2 h at 37oC in DMEM/F12 with 
2% BSA in combination with or 
without 8-bromo-cAMP (8b-cAMP) 
(10-3M). Glycerol concentrations (index of lipolysis) were determined using a fluorometric 
method (A). Values are means ± SD (n=5); *P<0.05. RNA was isolated from gWAT and mRNA 
levels of adipose triglyceride lipase (ATGL) and hormone sensitive lipase (HSL) were determined 
(B). Values are means ± SD (n=10); **P<0.01, ***P<0.001. gWAT cAMP levels were determined 
using a immunoassay kit (C). Values are means ± SD (n=9-10); *P<0.05. The anti-lipolytic 
effect of insulin was determined as % of 8b-cAMP induced lipolysis. Adipocytes were incubated 
with insulin (10-11M,10-9M and 10-7M) Statistical analysis was done using 2 way ANOVA (D). 
Values are means ± SD (n=5). mRNA levels of macrophage marker F4/80, mannose receptor C1 
(MRC-1), monocyte chemotactic protein-1 (MCP-1), interleukin 6 (IL-6) and interleukin 10 















a larger pool of preadipocytes, and a reduced number of very small adipocytes (<50µm). 
These results suggest that less preadipocytes are being recruited to become adipocytes in the 
gonadal adipose tissue, resulting in a higher pool of preadipocytes that remains in the SVF. 
So the CD36-/- mice seem to have a reduced adiposity not only due to a reduced hypertrophy 
but also due to a reduced hyperplasia of the adipocytes, at least in the gonadal adipose tissue.
The fact that the observed differences in preadipocyte recruitment seemed restricted 
to the gonadal tissue may be explained by the gonadal adipose tissue being the largest fat 
pad in the animals and that it has the largest fat cells, as also shown in this paper. We 
hypothesize that the gonadal adipose tissue was thus exposed to the highest metabolic 
stress and therefore the need for preadipocyte recruitment was probably the highest in this 
adipose tissue region. There were no differences in gene expression of CD36 between the 
subcutaneous and gonadal fat pads of WT mice (data not shown), so differential expression 
of CD36 cannot explain the observation that the gonadal fat is more affected. Gonadal fat 
depots are larger in male mice, both in absolute and relative terms. In male mice gonadal fat 
Figure 7. CD36-deficiency decreases hepatic insulin sensitivity. Wild-type (WT) and CD36-
deficient (CD36-/- mice) were fed a HFD for 11 weeks. After O/N fast a hyperinsulinemic 
euglycemic clamp was performed. Glucose infusion rate (GIR) (A), rate of disappearance during 
basal and hyperinsulinemic period (B) and hepatic glucose production during hyperinsulinemic 
period (C) were determined. Values are means ± SD (n=7-10 per group); *P<0.05, **P<0.01. 
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depots are larger than subcutaneous fat depots after HFD feeding, whereas in female mice 
the two fat depots are of almost equal size 17. The current study investigated only male mice, 
because male mice are more susceptible to diet-induced obesity and diet-induced insulin 
resistance than female mice 18. It remains to be studied whether in female mice changes in 
adipose tissue due to CD36-deficiency are less restricted to gonadal adipose tissue. 
Interestingly, despite the in vivo differences in adipocyte size distributions, isolated 
preadipocytes showed equal intra cellular lipid accumulation in vitro for CD36-/- mice and WT 
for all fat depots. Our results are in line with a recent study from Cai et al. that also showed similar 
differentiation capacity of the SVF of adipose tissue between WT and CD36-/- mice 19. These in 
vitro observations may be explained by de novo lipogenesis from carbohydrates present in the 
culture medium. Collins et al. have shown that de novo lipogenesis in differentiating adipocytes 
can provide all the FA that are necessary for adipocyte maturation. They showed this using 
an in vitro model of human preadipocytes which are cultured under serum free conditions 
without any exogenous fat 20. We added 10% FCS to our mouse preadipocyte cultures - as 
these cells cannot survive under serum free conditions- and serum contains FA. Despite the 
availability of exogenous FA as an energy source in our in vitro experiments, uptake of FA may 
have been by-passed and glucose was used instead to synthesize FA intracellularly. The fact that 
the gonadal adipose tissue of CD36-/- mice showed a reduced preadipocyte recruitment in the 
in vivo experiments may have been due to the high fat diet, which puts a maximum pressure 
on the expandability of the adipose tissue. The WT mice were able to cope with the FA overload 
by delivering them to the existing mature adipocytes as well as to the preadipocytes, whereas in 
the CD36-deficient mice neither mature adipocytes nor preadipocytes could efficiently take up 
the excess of FA. During preparation of this manuscript, a study was published by Christiaens 
et al. that showed impaired adipogenesis of 3T3-F442A preadipocytes upon CD36 silencing 
during preadipocyte differentiation 21. Whether the discrepancies between the studies are due 
to differences in cell type and/or CD36 expression level (none in our CD36-/- cells, low in the 
knock-down 3T3-F442A cell line) remains to be determined. 
 Gonadal adipocytes of CD36-/- mice showed increased basal and 8b-cAMP induced 
lipolysis. Published literature suggests that large adipocytes have a higher rate of lipolysis 22. 
However, we observed a higher basal- and 8b-cAMP stimulated lipolysis in adipocytes from 
CD36-/- mice, despite the decreased volume of these adipocytes. The increased lipolysis 
might be explained by diminished product inhibition of HSL by FA. Since CD36-deficiency 
impairs FA uptake by adipocytes, less FA might be present intracellularly which may 
lead to decreased product inhibition of HSL. Recently, it has been shown that long chain 
FA reduce production of cAMP which results in a decreased phosphorylation of HSL 23. 
Moreover, it has been shown that A-FABP null mice have decreased lipolysis, while E-FABP 
transgenic mice have increased lipolysis 24. This was explained by FABP being able to bind 
FA, thereby relieving product inhibition of HSL. We found an unexpected decrease in 
mRNA levels of ATGL and HSL in adipose tissue of CD36-/- mice compared to expression 
in WT mice. However cAMP levels were increased in CD36-/- mice, which results in 















the increased lipolysis. Since muscle normally relies on FA, it might also be that in CD36-/- 
mice there is a continuous signal from muscle to fat to release more FA and/or that there is 
absence of a stop signal to inhibit adipocyte lipolysis. Our results are in contrast with Zhou 
et al. who reported similar basal lipolysis and phosphorylation of HSL by WT and CD36-/- 
adipose tissue. This discrepancy could be due to the fact that Zhou et al. measured rates in 
incubated tissue versus adipocytes in the present study 25.
Insulin was more potent in inhibiting lipolysis in the CD36-deficient mice, suggesting 
higher insulin sensitivity of the adipocytes. Hypertrophic subcutaneous adipocytes were 
associated with increased insulin resistance 26-28. The fact that CD36-/- mice have less 
hypertrophic adipocytes could therefore help to explain the more potent inhibition of 
lipolysis by insulin. Kennedy et al. also observed increased insulin sensitivity in adipocytes 
from CD36-/- mice. They discovered that adipose tissue of HFD-fed CD36-/- mice is less 
inflamed, which could explain the increased insulin sensitivity 29. In accordance with these 
findings, we measured a decreased expression of the leukocyte marker CD45 as well as 
the macrophage marker F4/80 and found a trend towards higher expression of the anti-
inflammatory cytokine IL-10 in gonadal adipose tissue of the CD36 deficient mice. 
The observed reduction in body weight of CD36-/- mice on HFD is in accordance with 
recent studies by others, although the effect was less pronounced in our study (-6% versus 
-23% and -51% respectively) 6, 7.The smaller effect on body weight gain could be due to 
differences in HFD composition. We used a HFD containing 45 energy% of fat, whereas 
others used a HFD containing 60 energy% of fat 6, 7.
The reduced FA uptake in adipose tissue in CD36 deficient mice was paralleled by a 
reduced uptake in heart and an increased FA uptake in the liver and spleen. In contrast to the 
heart and muscle, CD36 is not a major facilitator of FA uptake in the liver, therefore FA uptake 
was not affected by the loss of CD36. Instead, the impaired uptake of FA in other peripheral 
organs such as muscle and adipose tissue results in a higher flux of FA to the liver. Our findings 
are partly in accordance with the study of Coburn et al. which showed that uptake of FA 
analogs was decreased in muscle and adipose tissue of chow-fed CD36-/- mice. We also found 
that the decreased FA uptake is solely caused by a lack of the FA transporter CD36 and not due 
to reduced capacity of lipoprotein lipase (LPL), since we found an even higher post-heparin 
LPL activity in CD36-/- mice (data not shown), probably due to compensatory mechanisms. 
The livers of the CD36-deficient mice contained more TG and were more insulin 
resistant as indicated by the higher hepatic glucose production under hyperinsulinemic 
conditions. It is well established that ectopic fat deposition in the liver contributes to 
development of hepatic insulin resistance 30, 31. Although the adipocytes of the CD36-/- 
mice showed increased insulin sensitivity in vitro; in vivo, we did not observe increased 
peripheral insulin sensitivity. This could be due to the fact that glucose uptake in adipose 
tissue under hyperinsulinemic conditions is relatively small. Under these conditions, most 
of the glucose is taken up by heart and muscle 32. 
One hypothesis to explain FA trafficking towards other places than adipose tissue, is the so 
called ‘sick adipose tissue’ hypothesis 33. According to this hypothesis unhealthy adipose tissue 
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consists of hypertrophic cells due to impaired creation of new adipocytes. Ultimately, these 
hyperthropic adipocytes become dysfunctional which results in increased FA release leading 
to increased FA availability to nonadipose tissues. Our study shows that CD36-deficiency 
also leads to ‘sick adipose tissue’. However, in this case the adipose tissue has dysfunctional 
adipocytes which cannot store an overload of FA together with an impaired ability to recruit 
new adipocytes. As a consequence, the FA are translocated to the liver. Despite the lack of 
hypertrophic adipocytes, CD36 deficient adipose tissue has an unexpected higher FA release 
during basal lipolysis which even further increases the availability of FA to the liver. Therefore 
it appears that CD36 plays an important role in adipose tissue functionality- both by regulating 
FA uptake and release- and likewise the distribution of fat to adipose and non- adipose tissues.
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ABSTRACT
Systemic inflammation is strongly involved in the pathophysiology of the metabolic 
syndrome, a cluster of metabolic risk factors including hypertriglyceridemia. Aspirin 
treatment lowers inflammation via inhibition of NF-κB activity, but also reduces 
hypertriglyceridemia in humans. The aim of this study was to investigate the mechanism 
by which aspirin improves hypertriglyceridemia. Human apolipoprotein CI (apoCI)-
expressing mice (APOC1 mice), an animal model with elevated plasma triglyceride (TG) 
levels, as well as normolipidemic wild-type (WT) mice were fed a high-fat diet (HFD) 
and treated with aspirin. Aspirin treatment reduced hepatic NF-κB activity in HFD-fed 
APOC1 and WT mice and in addition, aspirin decreased plasma TG levels (-32%; p<0.05) 
in hypertriglyceridemic APOC1 mice. This TG-lowering effect could not be explained 
by enhanced VLDL-TG clearance, but aspirin selectively reduced hepatic production of 
VLDL-TG in both APOC1 (-28%; p<0.05) and WT mice (-33%; p<0.05) without affecting 
VLDL-apoB production. Aspirin did not alter hepatic expression of genes involved in FA 
oxidation, lipogenesis and VLDL production, but decreased the incorporation of plasma-
derived FA by the liver into VLDL-TG (-24%; p<0.05), which was independent of hepatic 
expression of genes involved in FA uptake and transport. We conclude that aspirin improves 
hypertriglyceridemia by decreasing VLDL-TG production without affecting VLDL particle 
production. Therefore, the inhibition of inflammatory pathways by aspirin could be an 

















The metabolic syndrome is a clustering of metabolic risk factors, including steatosis, insulin 
resistance and hyperlipidemia, predisposing to the early onset of atherosclerosis and 
cardiovascular morbidity and mortality. It is well established that the metabolic syndrome 
is associated with increased systemic inflammation.1 Moreover, accumulating evidence 
suggests a strong involvement of systemic inflammation in the pathogenesis of components 
of the metabolic syndrome.2 Hypertriglyceridemia, one of the components of the metabolic 
syndrome and an important risk factor for the development of cardiovascular disease, is 
strongly associated with increased inflammation.3 Early studies show that sepsis, infection 
and inflammation are accompanied by hypertriglyceridemia.4-6 More recent studies 
show that administration of LPS induces hypertriglyceridemia.7,8 In addition, multiple 
cytokines, such as IL-6 and TNF-α, increase serum triglyceride (TG) levels.9,10 Inhibition 
of inflammation might therefore be an attractive therapeutic target in patients with HFD-
induced hypertriglyceridemia.
Non-steroidal anti-inflammatory drugs (NSAID) such as aspirin are known to inhibit 
the enzyme cyclooxygenase (COX). In addition, high doses of aspirin lower activation of 
inflammatory pathways by inhibition of the NF-κB pathway,11,12 which plays a crucial role in 
the inflammation-mediated pathogenesis of the metabolic syndrome.2 Interestingly, aspirin 
treatment diminishes hypertriglyceridemia in both obese rodents13 and patients with type 
2 diabetes mellitus.14 However, the mechanism underlying this TG-lowering effect still has 
to be elucidated.
We previously found that human apolipoprotein CI (apoCI)-expressing (APOC1) 
mice have increased plasma TG, by a diminished clearance of VLDL particles through 
apoCI-mediated inhibition of lipoprotein lipase (LPL),15 which is aggravated by high-fat 
diet (HFD) feeding (unpublished observation by I.O.C.M. Vroegrijk et al). Therefore, we 
reasoned that the HFD-fed APOC1 transgenic mouse is an appropriate model to study the 
effectiveness of treatments targeting HFD-induced hypertriglyceridemia. 
The aim of this study was to investigate the mechanism by which aspirin reverses HFD-
induced hypertriglyceridemia. Therefore, we studied the effect of aspirin on VLDL-TG 
metabolism in vivo in HFD-fed hypertriglyceridemic APOC1 mice as well as in C57Bl/6 
wild-type (WT) mice, to extend any findings towards the mouse model that is most widely 
used for evaluation of treatments for the metabolic syndrome. Our results show that a high 
dose of aspirin improves hypertriglyceridemia as a consequence of a clear reduction of 
hepatic VLDL-TG production, mediated by a diminished hepatic incorporation of plasma-
derived FA into VLDL-TG.
3.1 INTRODUCTION
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Animals, diet and aspirin treatment
Transgenic APOC1 mice with hemizygous expression of the human APOC1 gene were 
generated as previously described and backcrossed at least 10 times to the C57Bl/6 
background. The APOC1 mouse model develops hypertriglyceridemia mainly due to a 
diminished clearance of VLDL particles through apoCI-mediated inhibition of lipoprotein 
lipase (LPL).16,17 Male APOC1 mice and WT mice (also on a C57Bl/6 background) were 
housed under standard conditions with a 12-hour light-dark cycle. At the age of 10–12 
weeks, mice received a HFD (45 energy% derived from palm oil; D12451, Research Diet 
Services, Wijk bij Duurstede, The Netherlands) for a period of 6 weeks. Aspirin treatment 
(120 mg/kg/day in drinking water; pH 6.4) was given during the last 4 weeks on HFD and 
mice were subsequently used for experiments after an overnight fast at 9:00 am. Control 
mice received the same drinking water of pH 6.4 without the addition of aspirin. Mice 
were allowed free access to food and water. Animal experiments were approved by the 
institutional ethical committee on animal care and experimentation.
Liver NF-κB activation
Since the most common form of NF-κB is the p50/p65 heterodimer,18 the activity of both 
the p50 and p65 subunits in liver tissue was determined using electrophoretic mobility 
shift assay (EMSA).19 Shortly, tissues were homogenized in ice-cold Passive Lysis Buffer 
(Promega, Madison, WI) and centrifuged (14,000 rpm; 20 min; 4ºC). Protein content of 
the supernatant was determined using the BCA protein assay kit (Pierce, Rockford, IL). 
For the EMSA, the gel shift assay system was purchased from Promega. The probe was end-
labeled using T4 polynucleotide kinase and [32P]ATP and purified on a Microspin G-25 
column (GE Healthcare, Piscataway, NJ). For each sample, 50 µg protein was incubated 
with labelled probe and binding buffer (Promega) for 20 min at RT. Specific competition 
was done by adding unlabeled NF-kB binding probe to the reaction. The mixtures were run 
on 4.5% polyacrylamide gel electrophoresis in 0.5x Tris/Borate/EDTA (TBE) buffer. The gel 
was vacuum-dried and exposed to radiographic film.
Plasma parameters 
Blood was collected from the tail vein into chilled paraoxon (Sigma, St Louis, MO)-coated 
capillaries to prevent ongoing lipolysis.20 Capillaries were placed on ice, centrifuged 
and plasma was assayed for TG, total cholesterol (TC) and phospholipids (PL) using 
commercially available enzymatic kits from Roche Molecular Biochemicals (Indianapolis, 
IN) in 96-wells plates (Greiner Bio-One). Free fatty acids (FFA) were measured 
using NEFA-C kit from Wako Diagnostics (Instruchemie, Delfzijl, the Netherlands). 
ß-hydroxybutyrate (ß-HB) was determined using the enzymatic ß-HB Assay kit from 
BioVision (Mountain View, CA, USA)


















Lipids were extracted from livers according to a modified protocol from Bligh and Dyer.21 
Shortly, a small piece of liver was homogenized in ice-cold methanol. After centrifugation, 
lipids were extracted by addition of 1800 µL CH3OH:CHCl3 (3:1 v/v) to 45 µL homogenate. 
The CHCl3 phase was dried and dissolved in 2% Triton X-100. Hepatic TG and TC 
concentrations were measured using commercial kits as described earlier. Liver lipids were 
expressed per mg protein, which was determined using the BCA protein assay kit (Pierce).
Generation of VLDL-like emulsion particles
VLDL-like TG-rich emulsion particles were prepared and characterized as described 
previously.22,23 Lipids (100 mg) at a weight ratio of triolein: egg yolk phosphatidylcholine: 
lysophosphatidylcholine: cholesteryl oleate: cholesterol of 70: 22.7: 2.3: 3.0: 2.0, 
supplemented with 200 µCi of glycerol tri[9,10(n)-3H]oleate ([3H]TO) were sonicated at 
10 µm output using a Soniprep 150 (MSE Scientific Instruments, Crawley, UK). Density 
gradient ultracentrifugation was used to obtain 80 nm-sized emulsion particles, which were 
used for subsequent experiments. TG content of the emulsions was measured as described 
above. Emulsions were stored at 4°C under argon and used within 7 days.
In vivo clearance of VLDL-like emulsion particles
To study in vivo clearance of the VLDL-like emulsion particles, overnight fasted mice 
were anesthetized by intraperitoneal injection of acepromazine (6.25 mg/kg Neurotranq, 
Alfasan International BV, Weesp, The Netherlands), midazolam (6.25 mg/kg Dormicum, 
Roche Diagnostics, Mijdrecht, The Netherlands), and fentanyl (0.31 mg/kg Janssen 
Pharmaceuticals, Tilburg, The Netherlands). Mice were injected (t=0) via the tail vein with 
200 µL of [3H]TO-labeled emulsion particles at a dose of 100 µg of TG per mouse. Blood 
samples were taken from the tail vein at 1, 2, 5, 10 and 15 minutes after injection and plasma 
3H-activity was counted. Plasma volumes were calculated as 0.04706 x body weight (grams) 
as determined from 125I-BSA clearance studies as described previously.24 After taking the 
last blood sample, the liver, heart, spleen, muscle and white adipose tissue (i.e. gonadal, 
subcutaneous and visceral) were collected. Organs were dissolved overnight at 60°C in 
Tissue Solubilizer (Amersham Biosciences, Rosendaal, The Netherlands) and 3H-activity 
was counted. Uptake of [3H]TO-derived radioactivity by the organs was calculated from 
the 3H activity in each organ divided by plasma-specific activity of [3H]TG and expressed 
per mg wet tissue weight.
Hepatic VLDL-TG and VLDL-apoB production
To measure VLDL production in vivo, mice were fasted overnight as described above. 
Mice were injected intravenously with Tran35S label (150 µCi/mouse; MP Biomedicals, 
Eindhoven, The Netherlands) to label newly produced apoB. After 30 minutes, at t=0 
min, Triton WR-1339 (Sigma-Aldrich) was injected intravenously (0.5 mg/g body weight, 
10% solution in PBS) to block serum VLDL clearance. Blood samples were drawn before 
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(t=0) and 15, 30, 60 and 90 min after injection and used for determination of plasma TG 
concentration as described above. After 120 min, mice were exsanguinated via the retro-
orbital plexus. VLDL was isolated from serum after density gradient ultracentrifugation at 
d<1.006 g/mL by aspiration25 and counted for incorporated 35S-activity.
Hepatic gene expression analysis
Total RNA was extracted from liver tissues using the Nucleospin RNA II kit (Macherey-
Nagel, Düren, Germany) according to the instructions of the manufacturer. The quality of 
each mRNA sample was examined by lab-on-a-chip technology using Experion Stdsens 
analysis kit (Biorad, Hercules, CA). 1 µg of total RNA was reverse-transcribed with iScript 
cDNA synthesis kit (Bio-Rad) and obtained cDNA was purified with Nucleospin Extract II 
kit (Macherey-Nagel). Real-Time PCR was carried out on the IQ5 PCR machine (Biorad) 
using the Sensimix SYBR Green RT-PCR mix (Quantace, London, UK). mRNA levels 
were normalized to mRNA levels of cyclophilin (Cyclo) and glyceraldehyde-3-phosphate 
dehydrogenase (Gapdh). Primer sequences are listed in table 1. 
Contribution of plasma FA to VLDL-TG production
To measure the contribution of plasma derived FA to the VLDL-TG production in vivo, 
mice were fasted overnight as described above. Mice received a continuous i.v. infusion of 
Table 1. Primers used for quantitative real-time PCR analysis.
















Acox1, acyl-Coenzyme A oxidase 1, palmitoyl; Apob, apolipoprotein B; Cd36, fatty acid translocase; 
Cpt1a, carnitine palmitoyltransferase 1a; Dgat1, diglyceride acyltransferase 1; Fabp1, fatty acid binding 
protein 1; Fasn, fatty acid synthase; Mttp, microsomal triglyceride transfer protein; Ppara, peroxisome 
proliferative activated receptor alpha; Slc27a2, fatty acid transport protein 2; Slc27a4, fatty acid transport 


















3H-labeled FA ([9,10(n)-3H] palmitic acid in PBS with 2% bovine serum albumin) at a rate 
of 100µL/h (1.6 µCi/h). After 2 hours of 3H-labeled FA infusion a blood sample was taken 
(t=0 min), and Triton WR-1339 (Sigma-Aldrich) was injected intravenously (0.5 mg/g body 
weight, 10% solution in PBS) to block serum VLDL clearance. Additional blood samples 
were drawn 15, 30, 60 and 90 min after injection and used for determination of 3H activity 
in the TG fraction. Lipids were extracted by adding 10 µL plasma to 3.25 mL extraction 
fluid (heptane/methanol/chloroform; 100:128:137 (v/v/v)). 3H-TG were subsequently 
separated from 3H-FA; 1mL potassium carbonate (0.1M K2CO3, pH 10.5) was added 
followed by vortexing and centrifugation (3600 rpm; 15 min), leading to an upper alkaline-
methanol-aqueous phase containing saponified 3H-FA and a lower chloroform-organic 
phase containing 3H-TG.26 A fraction (0.5 mL) of the total aqueous phase (2.45 mL) was 
counted for 3H in scintillation fluid. The amount of 3H-TG in each sample was calculated by 
distracting total 3H-FA activity from total 3H activity. 
Statistical analysis
Data are presented as means ± SD. Statistical differences were calculated using the Mann-
Whitney test for two independent samples with SPSS 16.0 (SPSS Inc, Chicago, IL). P<0.05 
was regarded statistically significant.
Aspirin reduces hepatic NF-κB activation
To verify that aspirin inhibits hepatic NF-κB activity, the activities of the NF-κB subunits 
p50 and p65 were measured in livers of APOC1 and WT mice fed a HFD and treated with 
or without aspirin using a gel shift assay (Fig. 1). Aspirin indeed reduced the activity of 
both p50 (-69%; P<0.05) and p65 (-48%; P<0.05) in APOC1 mice (Fig. 1A) and the activity 
of p50 in WT mice (-72%; P<0.05), while the reduction in the activity of p65 did not reach 
statistical significance (P=0.13) (Fig. 1B).
Aspirin lowers plasma triglyceride and cholesterol levels in HFD-fed  
APOC1 mice
To examine whether aspirin could reduce hypertriglyceridemia in APOC1 mice, 
hyperlipidemic APOC1 mice were fed a HFD for 6 weeks and treated with or without aspirin 
and plasma lipids were determined (Fig. 2). Treatment of mice with aspirin reduced plasma 
TG levels by -32% (3.94 ± 0.15 to 2.67 ± 0.59 mmol/L; P<0.05; Fig. 2A) and plasma TC levels 
by -33% (4.09 ± 0.52 to 2.76 ± 0.90 mmol/L; P<0.05; Fig. 2B). Aspirin treatment did not 
affect plasma PL levels (Fig. 2C) and FFA levels (Fig. 2D). The reduction in plasma TG and 
TC levels was not caused by a reduction in body weight, since aspirin did not affect body 
weight in APOC1 mice (control: 30.5 ± 2.1 g; aspirin: 28.9 ± 3.0 g). In WT mice fed a HFD 
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Figure 1. Aspirin reduces hepatic NF-κB activation. APOC1 and WT mice were fed a HFD for 
6 weeks and treated without or with aspirin. Mice were sacrificed after an overnight fast and 
hepatic NF-κB activity was measured by electrophoretic mobility shift assay in liver tissue of 
APOC1 (A) and WT (B) mice treated without (open bars) or with (closed bars) aspirin. Activities 
of subunits p50 and p65 were measured. Values are means ± SD (n=3-4). *P<0.05
for 6 weeks, aspirin did not affect plasma TG, TC, PL or FFA levels (Fig. 2E-H). In addition, 
aspirin did not affect body weight in WT mice (control: 30.3 ± 2.1 g; aspirin: 30.8 ± 1.9 g)
Aspirin attenuates VLDL-like emulsion particle-TG clearance in HFD-fed 
APOC1, but not WT mice
A reduction in fasted plasma TG levels can be explained by an increase in VLDL-TG clearance 
and/or a decrease in hepatic VLDL-TG production. To determine whether aspirin enhances 
the clearance of VLDL-TG, the plasma clearance and organ distribution of [3H]-TO-
labeled TG-rich VLDL-like emulsion particles was evaluated in aspirin and control treated 
hypertriglyceridemic APOC1 mice (Fig. 3). Unexpectedly, aspirin inhibited, rather than 
enhanced, serum clearance of [3H]TO (t ½ = 15.9 ± 6.6 vs 5.6 ± 2.6 min) (Fig. 3A) in APOC1 
mice. This reduction in [3H]TO clearance upon aspirin was reflected by reduced uptake of 
[3H]TO-derived radioactivity by the liver by -60% (123 ± 1 vs 308 ± 75 nmol/g; P<0.05), by 
skeletal muscle by -66% (11 ± 2 vs 31 ± 15 nmol/g; P<0.05) and by white adipose tissue (WAT), 
which reached statistical significance for gonadal WAT (12 ± 3 vs 44 ± 22 nmol/g; P<0.05) 
(Fig. 3B). Apparently, aspirin reduces rather than enhances TG clearance in APOC1 mice 
and can, therefore, not explain the aspirin-induced reduction in VLDL-TG. In WT mice 
fed a HFD for 6 weeks, aspirin did not affect plasma clearance of [3H]TO (Fig. 3C) or organ 
specific uptake of [3H]TO-derived radioactivity (Fig. 3D) in WT mice. Apparently, the 
decreasing effect of aspirin on TG clearance may be specific for APOC1 mice.
Aspirin lowers VLDL-TG production in HFD-fed APOC1 and WT mice
Because the decrease in plasma TG levels in APOC1 mice upon aspirin treatment was not 
caused by increased TG clearance, we investigated whether the decreased TG levels could be 
explained by diminished hepatic VLDL-TG production in APOC1 mice. The rate of hepatic 

















Figure 2. Aspirin lowers plasma triglyceride and cholesterol levels in HFD-fed APOC1 mice. 
Plasma triglycerides (TG) (A&E), total cholesterol (TC) (B&F), phospholipids (PL) (C&G) 
and free fatty acid (FFA) (D&H) levels were measured in plasma of overnight-fasted HFD-fed 
APOC1 and WT mice treated without or with aspirin. Values are means ± SD (n=4-5). *P<0.05. 
55
Figure 3. Aspirin attenuates TG clearance of VLDL-like emulsion particles in HFD-fed APOC1, 
but not WT mice. HFD-fed APOC1 and WT mice that were treated without or with aspirin 
were fasted overnight and injected with [3H]TO-labeled VLDL-like emulsion particles. Blood 
was collected at the indicated time points and radioactivity was measured in plasma of APOC1 
(A) and WT (C) mice treated without (open circles) or with (closed circles) aspirin. Uptake of 
[3H]TO-derived activity by various organs was determined, and total FA uptake was calculated 
from the specific activity of TG in plasma, and expressed as nmol FA per mg wet tissue weight in 
APOC1 (B) and WT (D) mice. Values are means ± SD (n=4). *P<0.05. WAT, white adipose tissue; 
intest, intestinal; sc, subcutaneous; gon, gonadal.
Triton WR1339 injection (Fig 4). We found a reduction in hepatic VLDL-TG secretion rate in 
APOC1 mice treated with aspirin by -28% (3.42 ± 0.53 vs 4.95 ± 1.11 mM/h; P<0.05) (Fig. 4A), 
whereas aspirin did not affect the rate of VLDL-apoB production (Fig. 4B). Interestingly, 
similar to our observation in APOC1 mice, aspirin did reduce the hepatic VLDL-TG 
secretion rate in HFD-fed WT mice by -33% (2.79 ± 0.47 mM/h vs 4.19 ± 0.48 mM/h; P<0.05; 
Fig. 4C), whereas VLDL-apoB production rate was also not affected (Fig. 4D). Apparently, 
aspirin generally reduces the VLDL-TG production in HFD-fed mice, independent of the 
genotype. Furthermore, since each VLDL particle contains a single apoB molecule, this 
observation shows that aspirin treatment inhibits hepatic VLDL-TG production, without 

















Aspirin does not affect liver lipid levels in HFD-fed APOC1 and WT mice
To determine whether the attenuation in hepatic VLDL-TG production was the result 
of decreased lipid substrate availability in the liver, the effect of aspirin on hepatic lipid 
content was measured (Fig. 5). However, aspirin did not affect liver TG levels (Fig. 5A) and 
TC levels (Fig. 5B) in APOC1 mice. Also, aspirin did not affect liver TG (Fig. 5C) or TC 
(Fig. 5D) levels in WT mice.
Aspirin treatment does not affect hepatic expression of genes involved in 
FA oxidation, lipogenesis or VLDL production
Since changes in hepatic gene expression could underlie the reduction in VLDL-TG 
production, we determined the effect of aspirin on expression of genes involved in FA 
Figure 4. Aspirin decreases VLDL-TG production in HFD-fed APOC1 and WT mice. APOC1 
and WT mice were fed a HFD and treated without or with aspirin. Overnight fasted mice were 
injected with Trans35S and TritonWR1339 and blood samples were drawn at the indicated time 
points. TG concentrations were determined in APOC1 (A) and WT (C) mice treated without 
(open circles) or with (closed circles) aspirin and plotted as the increase in plasma TG relative to 
t=0 (A). After 120 min, VLDL was isolated by ultracentrifugation, 35S-activity was counted and 
the production rate of newly synthesized VLDL-35S-apoB was determined for APOC1 (B) and 
WT (D). Values are means ± SD (n=5). *P<0.05.
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oxidation, lipogenesis and VLDL production (Table 2). In both APOC1 and WT mice, 
aspirin did not affect expression of peroxisome proliferative activated receptor alpha (Ppara), 
a transcription factor that regulates genes involved in FA oxidation and ketogenesis, nor did it 
affect its target genes acyl-Coenzyme A oxidase 1 (Acox1) and carnitine palmitoyltransferase 
1a (Cpt1a). In line with these results, aspirin did not increase plasma ß-HB levels in WT 
mice (data not shown), which is a plasma marker for hepatic FA oxidation and ketogenesis. 
This implies that the reduced VLDL-TG production upon aspirin treatment is not caused 
by increased hepatic FA oxidation. We additionally determined the effect of aspirin on 
expression of genes involved in lipogenesis. In both APOC1 and WT mice, aspirin did not 
affect expression of sterol regulatory element binding protein 1c (Srebp-1c), which regulates 
genes required for de novo lipogenesis, nor did it affect acyl:diacylglycerol transferase 1 
(Dgat1), which catalyzes the final and only committed step in TG synthesis, or FA synthase 
(Fas), which plays a key role in FA synthesis. These data suggests that aspirin does not affect 
genetic regulation of de novo lipogenesis. In addition, aspirin did not affect hepatic gene 
expression of microsomal TG transfer protein (Mttp) which is involved in the assembly 
and secretion of VLDL. Furthermore, aspirin does not affect hepatic gene expression of 
Figure 5. Aspirin does not affect liver lipids in HFD-fed APOC1 and WT mice. Livers were 
collected from overnight-fasted HFD-fed APOC1 and WT mice treated without or with aspirin. 
Lipids were extracted and triglyceride (TG, A&C) and total cholesterol (TC, B&D) concentrations 

















apoB (Apob) in APOC1 mice, which is in line with the observation that aspirin does not 
affect VLDL-apoB secretion in vivo. However, despite the fact that aspirin did not affect 
VLDL-apoB secretion in WT mice, gene expression of Apob was increased in WT mice.
Aspirin treatment decreases the contribution of plasma-derived FA to  
the VLDL-TG production
Because the decrease in VLDL-TG production was not caused by a reduced hepatic 
lipid content or decreased expression of genes involved in de novo lipogenesis that could 
reduce lipid availability for VLDL-TG secretion, we investigated whether the decreased 
VLDL-TG production could be explained by a diminished contribution of plasma derived 
FA for VLDL-TG secretion in WT mice (Fig. 6). The contribution of plasma derived FA 
Table 2. Aspirin generally does not affect hepatic expression of genes involved in FA uptake and 
transport, FA oxidation, lipogenesis or VLDL secretion.
APOC1 WT
Gene Protein Control Aspirin p-value Control Aspirin p-value
FA uptake and transport
   Fabp1 FABP1 1.00 ± 0.37 0.73 ± 0.35 0.22 1.00 ± 0.41 0.61 ± 0.25 0.14
   Slc27a2 FATPa2 1.00 ± 0.45 1.23 ± 0.49 0.46 1.00 ± 0.33 0.74 ± 0.16 0.14
   Slc27a4 FATPa4 1.00 ± 0.35 1.74 ± 0.51 0.13 1.00 ± 0.44 1.01 ± 0.47 0.77
   Slc27a5 FATPa5 1.00 ± 0.17 1.20 ± 0.39 0.18 1.00 ± 0.40 0.96 ± 0.31 0.62
   Cd36 CD36 1.00 ± 0.58 1.75 ± 0.40 0.05 1.00 ± 0.80 0.45 ± 0.22 0.23
FA oxidation
   Ppara PPARα 1.00 ± 0.29 1.12 ± 0.46 0.62 1.00 ± 0.37 0.72 ± 0.18 0.18
   Acox1 ACO 1.00 ± 0.42 1.55 ± 0.55 0.14 1.00 ± 0.36 0.59 ± 0.12 0.09
   Cpt1a CPT1a 1.00 ± 0.55 1.36 ± 0.43 0.22 1.00 ± 0.10 0.96 ± 0.11 0.46
Lipogenesis
   Dgat1 DGAT1 1.00 ± 0.37 1.20 ± 0.11 0.29 1.00 ± 0.42 1.06 ± 0.53 0.85
   Fasn FAS 1.00 ± 0.42 1.05 ± 1.09 0.81 1.00 ± 0.40 0.97 ± 0.27 0.90
   Srebf1 SREBP-1c 1.00 ± 0.40 1.22 ± 0.53 0.41 1.00 ± 0.53 0.85 ± 0.68 0.72
VLDL secretion
   Apob ApoB 1.00 ± 0.46 1.20 ± 0.26 0.73 1.00 ± 0.32 1.59 ± 0.31* 0.03
   Mttp MTP 1.00 ± 0.37 0.87 ± 0.21 0.56 1.00 ± 0.39 1.21 ± 0.12 0.34
Livers were isolated from overnight fasted APOC1 and WT mice fed a HFD and treated without or 
with aspirin. mRNA was isolated and mRNA expression of the indicated genes was quantified by 
RT-PCR. Genes are grouped as genes involved in FA uptake and transport, FA oxidation, lipogenesis 
and VLDL production. Data are calculated as fold difference as compared to the control group. Values 
are means ± SD (n=4-5). *P<0.05 compared to control group. Acox1, acyl-Coenzyme A oxidase 1, 
palmitoyl; Apob, apolipoprotein B; Cd36, fatty acid translocase; Cpt1a, carnitine palmitoyltransferase 
1a, liver; Dgat1, diglyceride acyltransferase 1; Fabp1, fatty acid binding protein 1, liver; Fasn, fatty acid 
synthase; Mttp, microsomal triglyceride transfer protein; Ppara, peroxisome proliferative activated 
receptor alpha; Slc27a2, fatty acid transport protein 2; Slc27a4, fatty acid transport protein 4; Slc27a5, 
fatty acid transport protein 5; Srebpf1, sterol-regulatory element binding protein.
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3.4 DISCUSSION
was measured by determining plasma 3H-TG levels after continuous 3H-FA infusion and 
intravenous Triton WR1339 injection. We found that aspirin reduced hepatic 3H-TG 
secretion rate in WT mice by -24% (3.1 ± 0.4 vs 2.4 ± 0.7 x 103 dpm/h; P<0.05), which 
suggests that aspirin reduces VLDL-TG production by reducing the incorporation of 
plasma-derived FA into VLDL-TG. This reduction is not caused by a reduced hepatic 
expression of genes involved in hepatic FA uptake and transport (Table 2), since aspirin did 
not affect liver-type FA binding protein (Fabp1), FA transport proteins 2, 4 and 5 (Slc27a2, 
Slc27a4, Slc27a5) and even increased expression of FA translocase (Cd36) in APOC1, but 
not WT, mice. These data imply that aspirin reduced the VLDL-TG production independent 
of changes in hepatic expression of genes involved in FA uptake and transport.
Figure 6. Aspirin reduces the contribution of plasma derived FA to the VLDL-TG production.
WT mice were fed a HFD and treated without or with aspirin. Overnight fasted mice received 
a continuous i.v. infusion of 3H-labeled FA ([9,10(n)-3H] palmitic acid for 2 h, followed by an 
i.v. injection of TritonWR1339. Blood samples were drawn at the indicated time points and 3H 
activity in the TG fraction was determined in mice treated without (open circles) or with (closed 
circles) aspirin and plotted as the increase in plasma 3H-TG relative to t=0. Values are means ± 
SD (n=7). *P<0.05.
Treatment of obese rodents and patients with type 2 diabetes with high dose aspirin reduces 
hypertriglyceridemia.13,14 However, so far, the mechanistic basis for the relation between 
aspirin intake and reduced plasma TG levels has been poorly understood. In the present 
study we focused on the effects of aspirin on VLDL-TG metabolism in HFD-induced obese 
hyperlipidemic APOC1 mice and additionally evaluated the effects of aspirin on VLDL-TG 
metabolism in HFD-fed normolipidemic WT mice. Our results document that aspirin 
treatment improves hypertriglyceridemia by reducing the hepatic production of VLDL-TG 
as a result of an attenuated hepatic incorporation of plasma derived FA into VLDL-TG, 

















In the present study, aspirin treatment decreased plasma TG and TC levels in HFD fed 
APOC1 mice that display hypertriglyceridemia. This improvement in hyperlipidemia is in 
accordance with earlier studies, showing reduced serum TG concentrations upon aspirin or 
salicylate treatment in patients with type 2 diabetes mellitus14 and in diabetic rats.13 
Our data show that aspirin treatment attenuated the clearance of VLDL-like TG-rich 
particles in APOC1 mice. Therefore, the decrease in plasma TG levels by aspirin cannot be 
explained by increased TG clearance. Earlier studies report that high dose LPS injections 
reduce the clearance of TG-rich lipoproteins by inhibition of the LPL activity, mediated by 
cytokines.6,27 If indeed inflammation inhibits clearance of TG, inhibition of inflammation 
by aspirin is expected to increase TG-rich lipoprotein clearance, which is in contrast to our 
observation in APOC1 mice. It should be noted that aspirin, in addition to inhibition of 
inflammation via NF-κB, also inhibits prostaglandin synthesis, which has been demonstrated 
to restore the LPS-induced inhibition of LPL.28 Moreover, an early report has shown that 
aspirin treatment inhibits post-heparin LPL activity in humans.29 It would be interesting 
to elucidate the mechanism by which aspirin reduces the VLDL-TG clearance, however 
this is beyond the scope of the current manuscript as it does not explain the reduction in 
hypertriglyceridemia that we observe. Moreover, the observation may be a specific feature 
of the APOC1 transgenic mouse model, since we did not observe such an effect in WT mice.
Aspirin very effectively reduced hepatic secretion of VLDL-TG in APOC1 mice, 
explaining the reduction in hypertriglyceridemia upon aspirin treatment. In addition, 
aspirin equally reduced hepatic secretion of VLDL-TG in WT mice, indicating that the effects 
of aspirin on the VLDL-TG production do not exclusively occur in hypertriglyceridemic 
mouse models such as the APOC1 mouse. To our knowledge, we show for the first time 
that a decrease in inflammation corresponds with a drop in VLDL-TG production. The 
reduction of VLDL-TG secretion in our study is not paralleled by a reduction in apoB 
secretion in both APOC1 and WT mice, suggesting that aspirin reduces the lipidation 
of VLDL particles rather than reducing the number of particles that are secreted by the 
liver. In contrast to our data on apoB secretion, a recent study by Tsai et al30 observed that 
suppression of IKK with BMS345541 decreased apoB secretion in vitro in primary hamster 
hepatocytes and HepG2 cells. Even though differences between species might explain 
these conflicting findings, both these published in vitro studies and our present in vivo 
study point towards a link between the IKK/NF-κB pathway and the regulation of VLDL 
production. Moreover, we have recently shown that activation of the hepatic IKK/NF-κB 
pathway increases VLDL-TG production,31 supporting the hypothesis that the effects 
of aspirin on the VLDL-TG production are mediated via a reduction in hepatic NF-κB 
activity. Nevertheless, activation of hepatic IKK/NF-κB increases hepatic Fas expression,31 
while aspirin in the current study did not change hepatic expression of Fas, neither did it 
change expression of other genes involved in TG synthesis, such as Dgat1 and Srepb-1c, 
suggesting that aspirin more likely lowers VLDL-TG production by other mechanisms than 
via its effects on hepatic NF-κB activity. 
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A reduction in hepatic lipid availability by increased lipid oxidation could underlie the 
mechanism by which aspirin reduces hepatic VLDL-TG production. However, aspirin did 
not affect expression of genes involved in FA oxidation nor plasma levels of ß-HB, a marker 
of hepatic FA oxidation and ketogenesis. Similarly, aspirin did not affect expression of genes 
involved in de novo lipogenesis or VLDL production, suggesting that aspirin does not reduce 
VLDL-TG production by changing expression of genes involved in hepatic lipid metabolism. 
It has been suggested that the decrease in plasma TG concentration that occurs upon 
aspirin treatment might be secondary to the fall in plasma FFA levels.32 A reduction in FFA 
delivery to the liver could result in a reduced availability of FA for the release of VLDL-TG 
by the liver.33 Indeed, although aspirin did not change plasma FFA levels, it changed the 
turnover of FA as reflected by a -24% reduction in the incorporation of plasma derived 
FA into VLDL-TG, showing that aspirin in fact lowers the availability of plasma derived 
FA for VLDL-TG production. This reduction of FA incorporation into VLDL-TG upon 
aspirin treatment was not caused by a reduced hepatic expression of FA transporter 
proteins, suggesting that aspirin reduces the FA incorporation via another mechanism. It is 
possible that aspirin reduces posttranscriptional processing of FA transporters independent 
of mRNA expression, since expression of FA transporters does not always correlate with 
changes in protein content or the rate of FA transport.34 Alternatively, aspirin might 
increase FA uptake and transport via simple diffusion, since FA uptake has been described 
independent of any FA transporter.34 
The decrease of FA turnover that we observed could be secondary to an increased insulin 
sensitivity of adipose tissue, thereby decreasing FA mobilization to plasma. Indeed, high dose 
salicylates, such as aspirin have shown to increase insulin sensitivity13 and the reduction in 
VLDL-TG production in our study is similarly accompanied by an increased insulin sensitivity 
(unpublished observation). However, the aspirin-induced reduction in FA utilization and 
subsequent VLDL-TG secretion in our study were determined under fasting conditions, when 
the role of insulin is marginal. In fasting conditions, the lipolytic activity of adipocytes is 
stimulated by catecholamines. Interestingly, aspirin has been reported to reduce catecholamine-
stimulated lipolysis, which is therefore a more likely explanation for our findings.35,36 In 
addition, it has been shown that aspirin reduces release of FA from adipose tissue directly via 
inhibition of TNF-α induced lipolysis.37 We therefore propose that the fact that aspirin reduces 
plasma derived FA utilization by the liver, is likely caused via direct inhibition of intracellular 
lipolysis in adipose tissue, which reduces plasma FA availability. Adipose tissue lipolysis might 
be further inhibited in the fed state by an increased sensitivity for insulin.
In conclusion, our data show that aspirin inhibits NF-κB and decreases HFD-induced 
hypertriglyceridemia by reducing hepatic VLDL-TG secretion rather than by accelerating 
the tissue distribution of VLDL-TG. The reduction in VLDL-TG is not caused by a decreased 
steatosis, increased FA oxidation or changes in de novo lipogenesis, but by an attenuation of 
hepatic incorporation of plasma derived FA into VLDL-TG. In scope of our findings, aspirin 
could potentially be a new therapeutic drug in the treatment of hypertriglyceridemia. 

















other hand is a non-steroidal anti-inflammatory drug with similar structure that is regarded 
as a safer alternative. High-dose salsalate treatment has recently shown to reduce TG levels 
in diabetic patients similar to high-dose aspirin treatment,38 and could therefore potentially 
be a new drug for the treatment of hypertriglyceridemia.
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META060 PROTECTS AGAINST DIET-INDUCED 
OBESITY AND INSULIN RESISTANCE  
IN A HIGH-FAT DIET FED MOUSE4
ABSTRACT 
We investigated whether a reduced iso-alpha acid derived from an extract of Humulus 
lupulus L., META060, had an effect on weight gain, body composition and metabolism 
in a high fat diet (HFD) fed mouse. Weight gain was monitored for up to twenty weeks in 
mice receiving either a low fat diet, a high fat diet, or a high fat diet supplemented with 
META060 or rosiglitazone. Body composition was determined using DEXA scan analysis. 
Indirect calorimetry measurements were performed to investigate energy balance in the 
mice, and oral glucose tolerance tests were administered to examine the effect of META060 
on glycemic response. HFD-fed mice administered META060 for fourteen weeks had a 
significantly lower mean weight than that of HFD-fed mice (30.58 ± 0.5 g versus 37.88 ± 0.7 g; 
P<0.05). Indirect calorimetry measurements revealed increased metabolic flexibility in mice 
supplemented with META060. In addition, glucose tolerance was improved, comparable to 
the effects of rosiglitazone treatment. We conclude that META060 has potential therapeutic 
value for managing obesity and insulin resistance, and further research into the mechanism 






















Management of obesity has become a primary goal for healthcare practitioners in response 
to the rising epidemic of obesity related chronic diseases, including type 2 diabetes mellitus 
(T2DM) and cardiovascular disease. Pharmaceutical approaches that alter appetite, 
metabolism, or fat absorption include antidepressants, CNS stimulants, or peripherally 
acting antiobesity drugs, and all have been associated with adverse effects (reviewed 
in 1). Many people seek natural therapies as an alternative to pharmaceuticals for weight 
management. Yerba mate, yohimbe, aloe, pyruvate, St. John’s Wort, dandelion, and herbal 
diuretics have been used for weight loss, although significant clinical studies supporting 
their efficacy are lacking (reviewed in 2). 
Iso-alpha acids derived from the hop plant (Humulus lupulus L.) reduced plasma 
triglyceride and free fatty acid levels in mice 3, 4. C57BL/6N mice fed a high fat diet (HFD) 
exhibited improved glucose tolerance after 14 days and reduced insulin resistance after 
10 days of administration of iso-alpha acids. Furthermore, in a double-blind, placebo-
controlled pilot study, diabetic subjects receiving iso-alpha acids for 8 weeks had an average 
10.1% reduction in blood glucose levels and 6.4% reduction in glycated hemoglobin levels 4. 
Iso-alpha acids are not particularly stable compounds, although the reduced derivatives 
have been found to exhibit greater stability 5. Furthermore, reduced iso-alpha acids have 
recently demonstrated greater bioavailability than iso-alpha acids in humans 6. 
Previous work in our lab to screen various botanical extracts for lipogenic activity 
resulted in the identification of a family of reduced iso-alpha acids 7. One of the reduced 
iso-alpha acids, META060, has demonstrated anti-inflammatory activity in vitro, mediated 
by inhibition of NF-κB pathways 8, 9. Several reports have suggested a link between obesity-
induced inflammation and related metabolic disorders such as insulin resistance (reviewed 
in 10, 11). Objectives of the current study were to determine the effects of META060 compared 
with rosiglitazone, a commonly used drug in the treatment of T2DM, on body weight, 
energy metabolism, glucose tolerance and insulin sensitivity in HFD-induced obese mice. 
4.1 INTRODUCTION
4.2 MATERIALS AND METHODS
Animals and diet intervention
Wild-type (WT) C57Bl/6J male mice were purchased from Charles River (Maastricht, The 
Netherlands). Mice were housed under standard conditions with access to water and food 
ad libitum. For the 14-week diet intervention, the study was started when the animals were 
19 weeks of age. Mice were fed either a low fat diet (LFD) (10% energy derived from lard 
fat; D12450, Research Diet Services, Wijk bij Duurstede, The Netherlands), with a caloric 
content of 3.85 kcal/g, a high fat diet (HFD) (45% energy derived from lard fat; D12451, 
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Research Diet Services, Wijk bij Duurstede, The Netherlands), with a caloric content of 4.73 
kcal/g, or a HFD supplemented with META060 (100 mg/kg/day) or rosiglitazone (1 mg/
kg/day) (SmithKline Beecham Farma, Rijswijk, The Netherlands). META060 was supplied 
by Hopsteiner, and standards were purchased from ASBC. The chemical composition of 
META060 has been described previously 12. META060 or Rosiglitazone were added to 
self-made HFD. Briefly, rosiglitazone tablets (Avandia® = rosiglitazone maleate, SmithKline 
Beecham Farma, Rijswijk, The Netherlands) or META060 powder were crushed in a mortar 
with a pestle. Subsequently, the powder was mixed with the 45% lard HFD powder diet from 
Research Diets Service (45% energy derived from lard fat; D12451, Research Diet Services, 
Wijk bij Duurstede, The Netherlands). For HFD + META060, 1.875 g of META060 per kg of 
HFD powder was used. For rosiglitazone, 12 mg powder was added to 1 kg of HFD powder. 
Pellets were made by adding 2% agar (Sigma), and were then freeze-dried to remove water 
and stored at -20oC. A fixed dosage was used throughout the diet intervention. Based on 
previously assessed food intake data we know that C57Bl/J6 mice on a HFD+META060 diet 
(D12451, Research Diet Services diet) eat ~2.5 g of diet per day. Each treatment group in 
the 14-week intervention included 12 mice, and mice were weighed weekly. Food intake was 
monitored weekly by weighing the food in the cages manually. After 14 weeks, animals in the 
LFD or HFD plus rosiglitazone groups were sacrificed, following 4 hours of fasting. Mice from 
the HFD group were randomly divided into 2 groups: six were shifted to HFD plus META060 
(100 mg/kg/day), and the remaining six mice continued receiving a HFD for six weeks. 
Likewise, mice supplemented with HFD plus META060 were divided into 2 groups: six were 
shifted to HFD, and the remaining six mice continued receiving HFD plus META060. 
For the 5-week diet intervention, 12-week-old mice were fed a HFD, a HFD 
supplemented with META060 (100 mg/kg/day), or a HFD supplemented with rosiglitazone 
(1 mg/kg/day). Each dietary group consisted of 9 animals. Body weight was measured 
weekly during the diet intervention. All experiments were approved by the animal ethics 
committee of Leiden University Medical Center. 
DEXA Scan
Animals were subjected to DEXA scan analysis after 4 hours of fast. Animals were weighed 
and sedated by a single intraperitoneal injection of a mixture of acepromazine (6.25 mg/kg 
Neurotranq, Alfasan International BV, Weesp, The Netherlands), midazolam (6.25 mg/kg 
Dormicum, Roche Diagnostics, Mijdrecht, The Netherlands), and fentanyl (0.31 mg/kg 
Janssen Pharmaceuticals, Tilburg, The Netherlands). Sedated animals were scanned in toto 
using a small animal DEXA scanner (pDEXA, Norland Stratec Medizintechinik GmbH, 
Birkenfeld, Germany) and data were analyzed by the software supplied by the manufacturer. 
Fat mass and lean body mass were determined.
Indirect calorimetry
Groups of 8 mice were subjected to individual indirect calorimetry measurements for a 






















System (Columbus Instruments, Columbus Ohio, US). Cages were made of clear plexiglass 
(30 x 10 x 9 cm (l x b x h)). Prior to the start of the experiment, animals were acclimated 
to the cages and the single housing for a period of 24 h. Experimental analysis started at 
09:00 h and continued for 36 hours. In the next 36 hours of monitoring, animals were fasted 
overnight, and then food was replaced to assess metabolic flexibility. Analyzed parameters 
included real time food and water intake, as well as meal size, frequency and duration. 
Oxygen consumption (VO2) and carbon dioxide production rates (VCO2) were measured 
at intervals of 7 minutes. Respiratory exchange ratio (RER) as a measure for metabolic 
substrate choice was calculated as the ratio between VCO2 and VO2. Carbohydrate (CHO) 
and fat (FA) oxidation rates were calculated using the following formulas 13:
CHO = ((4.585 * VCO2) – (3.226 * VO2)) * 4 / 1000
FA = ((1.695 * VO2) – (1.701 * VCO2)) * 9 /1000
Total energy expenditure was calculated from the sum of CHO and FA oxidation. 
Activity was monitored as 2-dimensional infrared beam breaks.
Fecal fatty acid composition and concentration
Feces were collected over 4 days during week 4 of the 5-week diet intervention. Feces were 
weighed, freeze-dried, and ground, and fecal fatty acids (FA) were subsequently derivatized 
by methyl esterification. Therefore, 2 mL methanol/hexane (4:1 v/v) containing 80 µg 
pentadecanoic acid (C15:0) as an internal standard (Fluka) was added to 15 mg feces. 
Then, 200 µL acetyl chloride (Merck) was added, and samples were incubated at 95°C. 
After subsequent cooling to 4°C, 5 mL 6% K2CO3 (Sigma) was added and samples were 
centrifuged (10 min, 4000 rpm, 4°C). The upper hexane layer was isolated and used for GC 
analysis of FA methyl esters (FAME). FAME were separated on a 50 m x 0.25 mm capillary 
GC column (CP Sil 88, Agilent technologies) in a 3800 GC gas chromatograph (Varian) 
equipped with a flame ionization detector. The injector and flame ionization detector were 
kept at 270°C. The column temperature was programmed from 170°C to 210°C. FAME were 
introduced by split injection (split ratio 20:1). Quantification was based on the area ratio of 
the individual FA to the internal standard.
Oral glucose tolerance test
Glucose and insulin levels were determined after overnight fasting during week 5 of the 
5-week diet intervention, and also after 14 weeks of the 14-week diet intervention. Blood 
was obtained via tail bleeding, and glucose and insulin concentrations were determined. 
Subsequently, mice received an intragastric load of D-glucose (2 g/kg) provided as a 20% 
solution in PBS. Additional blood samples (30 μl) were collected via tail bleeding at 5, 15, 
30, 60, 90 and 120 min after glucose loading for measurement of plasma insulin and glucose 
concentrations. Glucose concentration was determined with a glucose analyzer (Accu-
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Check, Sensor Comfort, Roche Diagnostics GmbH, Germany) and insulin concentration 
was determined by immunoassay (Chrystal Chem Inc). 
Statistical Analysis
Data are presented as means ± SE. Statistical differences were calculated using the unpaired 
t-test (SPSS 17, SPSS Inc, Chicago, IL) or 2-way Analysis of Variance with Bonferroni posttest 
(GraphPad Prism, San Diego, CA). A P-value <0.05 was regarded as statistically significant.
4.3 RESULTS
Supplementation with META060 for 14 weeks prevents HFD-induced obesity 
To determine the effect of META060 on high fat diet (HFD)-induced obesity, mice were fed 
a low fat diet (LFD), a HFD, or a HFD supplemented with either 100 mg/kg/day META060 
or 1 mg/kg/day rosiglitazone for 14 weeks. Previous studies in a mouse model of collagen-
induced arthritis demonstrated an effect of META060 with 50 mg/kg/day for reducing 
cartilage degradation and bone erosion, and doses up to 250 mg/kg/day were well tolerated 8. 
Therefore, a dose of 100 mg/kg/day was selected for the current study investigating the effect of 
META060 on body weight and metabolism in HFD fed mice. Rosiglitazone is an antidiabetic 
agent from the thiazolidinedione class of drugs. Its mechanism of action is well-known, 
involving activation of PPARγ, and studies in HFD fed mice demonstrated reduction of 
insulin levels with a dose of 1 mg/kg/day rosiglitazone 14. Mice receiving HFD supplemented 
with META060 maintained similar body weights to those on a LFD over 14 weeks , and 
were significantly lower in weight than HFD-fed mice at week 3 and every subsequent 
time point up to week 14 (Fig. 1A). After 14 weeks, META060 supplemented mice weighed 
19% less than HFD-fed control mice (30.58 ± 0.5 g versus 37.88 ± 0.7 g; P<0.05), and were 
comparable in weight to mice fed a LFD for 14 weeks (29.71 ± 0.7 g). Mice supplemented 
with rosiglitazone did not gain as much weight as those without supplementation, although 
they gained significantly more weight than HFD plus META060 or LFD fed mice (Fig. 1A). 
During the 14 week diet intervention no differences in food intake were observed.
To determine whether reduced weight gain in META060 supplemented mice reflected 
lower fat accumulation compared with HFD-only fed mice, body composition of these 
mice was determined by DEXA scan analysis. Total body fat of mice supplemented 
with META060 was significantly lower than that of HFD-fed mice (3.29 ± 1.0 g versus 
12.12 ± 1.1 g; P<0.001) (Fig. 1B). At the end of the experiment, organs were dissected and 
weighed. META060 supplementation reduced gonadal (1.17 ± 0.2 g versus 2.40 ± 0.09 g; 
P<0.001) and subcutaneous (0.47 ± 0.09 g versus 1.53 ± 0.2 g; P<0.001) white adipose tissue 
(WAT) mass in HFD-fed mice compared to no-supplement controls (Fig. 1C). 
At 15 weeks, half of the mice in the HFD group were shifted to HFD plus META060, and 






















Figure 1. META060 prevents high fat diet (HFD)-induced obesity. Mice were fed a low-fat diet 
(LFD), a HFD, or a HFD supplemented with either 100 mg/kg/day META060 or 1 mg/kg/day 
rosiglitazone (Rosi) for 14 weeks. Mouse body weights were recorded every week (n = 12 per 
group);**P<0.01, ***P<0.001 HFD vs. HFD + META060, ^P<0.05, ^^P<0.01, ^^^P<0.001 
HFD + META060 vs. HFD + Rosi, #P<0.05, ##P<0.01 HFD + META060 vs. LFD (A). After a 4 
h fast, lean body mass and fat mass were determined by DEXA scan (n = 6 per group for HFD 
and META060 and n=12 per group for Rosi); ***P<0.001 HFD vs. HFD + META060 and HFD vs 
HFD + Rosi (B). After mice were sacrificed, mass of gonadal White Adipose Tissue (gWAT) and 
subcutaneous WAT (sWAT) was determined (n=6 per group for HFD and META060 and n=12 
per group for Rosi); ***P<0.001 HFD vs. HFD + META060 and HFD vs HFD + Rosi (C). At 14 
weeks, half of the mice in the HFD group were shifted to HFD + META060, and half of the mice 
in the HFD + META060 group were shifted to HFD only. Body weights were recorded weekly 
(n=6 per group); *P<0.05, **P<0.01, ***P<0.001 HFD vs. HFD → HFD + META060, ^^P<0.01 
HFD + META060 vs. HFD + META060 → HFD (D). Data are presented as mean ± SE.
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was monitored weekly for 5 weeks in these 4 treatment groups. While animals maintained 
on HFD for the entirety of the experiment continued to gain weight, those shifted to HFD 
plus META060 lost a significant amount of weight during weeks 16 and 17, after which they 
began to gain weight again (Fig. 1D). A concomitant reduction in food intake was observed 
in the first two weeks after switching diets, followed by a rebound to even greater levels than 
food intake in the HFD plus META060 group that did not switch diets (data not shown), 
perhaps a reflection of adjustment to palatability differences between the distinct diets. 
META060 increases RER and metabolic flexibility in mice fed a HFD 
To investigate how META060 protects against HFD-induced obesity, an independent, 5-week 
study was initiated with three treatment groups: HFD; HFD supplemented with META060 
(100 mg/kg/d); or HFD supplemented with rosiglitazone (1 mg/kg/d). In the first five weeks 
of the 14-weeks intervention study, average weight gained in the HFD group was 5.61 ± 0.7 g, 
while mice supplemented with META060 gained 0.68 ± 0.3 g. In the 5-weeks study, average 
weight gained in the HFD group was 2.58 ± 0.4 g, and mice supplemented with META060 
gained 0.54 ± 0.9 g. (Fig. 2). Despite differences in absolute weight gained, which was likely 
due to the difference in age of mice at the start of each study, META060 supplementation 
reproducibly reduced relative HFD-induced body weight gain in both experiments. 
Whole body substrate utilization was examined for approximately 36 h during week 4 of the 
diet intervention. Four weeks of diet intervention was chosen because at this time point in the 
14-week study, body weight was still increasing and a new set point had not yet been reached. 
Although we did not directly compare a LFD group during the 5-week study, we know 
from published and experimental data that 5 weeks of HFD feeding in mice results in an 
Figure 2. Comparison of 5-weeks’ bodyweight increase in 5-weeks and 14-weeks studies. Mice 
were fed a high fat diet (HFD), HFD supplemented with META060, or HFD supplemented 
with rosiglitazone (Rosi) in two independent studies of varying durations, 5 weeks or 14 weeks. 
In both studies, mice were weighed at 5 weeks. Mean body weight difference from baseline is 






















unaltered total energy expenditure (EE) (kcal/h), but changes respiratory exchange rate 
(RER) and fat (FA) and CHO oxidation. Daytime RER was 0.84±0.04 versus 0.94±0.04, and 
night time RER was 0.84±0.03 versus 0.93±0.04, for HFD versus LFD, respectively (p<0.05). 
Daytime FA oxidation was 0.17±0.05 versus 0.07±0.04, and night time FA-oxidation was 
0.19±0.05 versus 0.08±0.06, for HFD versus LFD, respectively (p<0.05). META060 or Rosi 
intervention started from Day 0, when the animals were switched from chow to HFD as 
described in Materials and Methods.
Nocturnal and diurnal data were analyzed separately to distinguish between periods of 
low (diurnal) and high (nocturnal) physical activity. Total EE was similar across all dietary 
intervention groups (Fig. 3A). For food intake (FI), no significant differences were observed 
between the groups (data not shown). Despite similarities in total EE and FI, HFD-fed 
mice supplemented with META060 or rosiglitazone exhibited a significantly lower mean 
nocturnal FA oxidation rate than HFD only (0.16 ± 0.01 kcal/h and 0.18 ± 0.01 kcal/h versus 
0.22 ± 0.01 kcal/h; P<0.001, P<0.01, respectively), and rosiglitazone had a lower mean diurnal 
FA oxidation rate compared to that of control (0.12 ± 0.01 kcal/h versus 0.15 ± 0.01; kcal/h 
P<0.05) (Fig. 3B). In addition, nocturnal CHO oxidation levels were increased in HFD fed 
mice that received META060 or rosiglitazone, compared with controls (0.36 ± 0.02 kcal/h and 
0.35 ± 0.01 kcal/h versus 0.31 ± 0.01 kcal/h; P<0.01) (Fig. 3C). This increased carbohydrate-
to-fat oxidation ratio was reflected in the RER. META060 and rosiglitazone both significantly 
increased RER in HFD-fed mice during the diurnal period compared to HFD-only fed mice 
(0.88 ± 0.00 and 0.89 ± 0.01 versus 0.86 ± 0.01; P<0.05, P<0,01 respectively), and also during 
the nocturnal period (0.87 ± 0.01 and 0.86 ± 0.00 versus 0.83 ± 0.01; P<0.001, respectively) 
(Fig. 4A-B). To test the ability of the animals to adjust fuel oxidation to fuel availability 
(metabolic flexibility), animals were fasted overnight; subsequently, the food was replaced 
and RER was monitored. META060 and rosiglitazone supplemented mice had a significantly 
higher RER when the food was replaced compared to HFD-only treated mice (0.94 ± 0.00 and 
0.94 ± 0.00 versus 0.92 ± 0.00; P<0.001), indicating greater metabolic flexibility in META060 
or rosiglitazone fed animals (Fig. 4C). Physical activity measurements did not show differences 
in either treatment group compared with HFD-only fed mice (data not shown).
META060 has no effect on fecal fatty acid composition and concentration 
Since META060 reduced fat oxidation, we investigated whether fat absorption was impaired in 
META060 supplemented mice. Fecal fatty acid composition and concentration were determined 
in samples collected during metabolic cage experiments (data not shown). No difference was 
found in total fecal weight. Furthermore, quantitative gas chromatography analysis revealed 
equal fecal fatty acid composition and fecal fatty acid content in all treatment groups. Together 
with the equivalent food intake, this implies similar intestinal absorption of lipids.
META060 improves glucose tolerance in HFD fed mice
Since increased carbohydrate-to-fat oxidation ratio and increased metabolic flexibility 
suggest protection against HFD-induced insulin resistance, oral glucose tolerance tests 
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Figure 3. META060 affects substrate utilization. During week 4 of the diet intervention, 
O2 consumption and CO2 production were recorded for 36 h in HFD fed mice without 
supplementation or supplemented with 100 mg/kg/d META060 or 1 mg/kg/d rosiglitazone 
(Rosi). The night period is represented by the shaded area on the graph. EE was calculated as 
described in Methods (A). Fatty acid (FA) (B) and carbohydrate oxidation (CHO) (C) for day 
phase or night phase were calculated for HFD fed mice without supplementation or in those 























Figure 4. META060 increases respiratory exchange rate (RER) and metabolic flexibility. RER 
was monitored for 36 h in HFD fed mice without supplementation or supplemented with 
100 mg/kg/d META060 or 1 mg/kg/d rosiglitazone (Rosi) (A). RER for day phase or night phase 
was calculated for each treatment group (n=8 per group); *P<0.05, **P<0.01, ***P<0.001 (B). 
HFD fed mice with or without supplementation with META060 or Rosi for 4 weeks were fasted 
overnight and then feeding was resumed. RER was calculated after fasting (F) and after refeeding 
(R) (n=8 per group; *P<.05) (C). Data are presented as mean ± SE.
(OGTT) were performed during week 5 of the diet intervention. After an overnight fast, 
blood glucose concentration was lower in META060 supplemented mice compared to that 
of HFD-only treated mice (4.66 ± 0.2 versus 5.34 ± 0.3; P<0.05) (Fig. 5A), while fasting 
insulin levels were not significantly different among treatment groups (Fig. 5D). Following 
glucose challenge, plasma glucose and insulin levels were determined at time intervals up 
to 120 min, and areas under the curve (AUC) were calculated. Glucose concentrations 
were significantly decreased for mice supplemented with META060 compared to HFD-fed 
mice at 15 min, 30 min, 90 min, and 120 min after glucose challenge, and mean AUC 
was 20% lower than in HFD-fed mice (P<0.05) (Fig. 5B-C). Rosiglitazone also significantly 
decreased plasma glucose levels at 5, 30, 60, and 90 min after glucose challenge, and mean 
AUC was 15% lower than in HFD-fed mice (P<0.05). These observations demonstrate that 
META060 and rosiglitazone improved glucose tolerance in mice fed a HFD for 5 weeks. 
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This may be due to increased insulin sensitivity in response to an oral glucose load, since 
time course and AUC for plasma insulin levels were comparable in all groups (Fig. 5E-F).
After 14 weeks of diet-intervention, fasting blood glucose concentration in META060 
supplemented mice was significantly lower than that of HFD fed mice (4.5 ± 0.3 mM 
versus 5.9 ± 0.3 mM; P<0.05) (Fig. 6A). Moreover, fasting insulin concentration was also 
significantly reduced in META060-supplemented mice compared to that of HFD-fed mice 
(0.14 ± 0.05 ng/mL versus 0.42 ± 0.09 ng/mL; P<0.001) (Fig. 6C). This implies that after 
long-term META060 supplementation, insulin sensitivity in HFD-fed mice was increased. 
OGTT were performed on mice and blood glucose and insulin concentrations were 
recorded at several time points up to 120 min post-challenge. Area under the curve (AUC) 
for glucose was similar among all groups (Fig. 6B). However, AUC for insulin was increased 
in the HFD group, and only rosiglitazone supplementation had a statistically significant 
effect on reducing the insulin response compared to HFD (40%; P<0.05) (Fig. 6D). 
4.4 DISCUSSION
In the current study we investigated the effects of META060 on HFD-induced obesity and 
insulin resistance. Supplementation with META060 reduced weight gain in HFD fed mice. 
This effect was significant after 3 weeks, and was sustained for up to 20 weeks. Furthermore, 
when META060 feeding was terminated, mice began to gain weight rapidly. META060 
inhibited fat accumulation in HFD fed mice as evidenced by a reduction in adipose tissue 
mass in mice supplemented with META060 compared with HFD fed control mice. In 
addition, META060 improved glucose tolerance after 5 weeks of supplementation. Moreover, 
long-term META060 supplementation in HFD-fed mice clearly reduced fasting blood glucose 
and insulin levels. These data suggest that META060 improves glucose homeostasis similarly 
to rosiglitazone and prevents HFD-induced obesity and insulin resistance.
Rosiglitazone, an antidiabetic drug from the class of thiazolidinediones, increases insulin 
sensitivity through its action on peroxisome proliferator activated receptor gamma (PPARγ), 
and also has demonstrated anti-inflammatory activity through a mechanism involving nuclear 
factor kappa-B (NF-κB) 15, 16. While the mechanistic target(s) of META060 has not been identified, 
previous studies indicate that META060 has potent inhibitory effects on several kinases 
regulating the NF-κB pathway, including glycogen synthase kinase 3 (GSK-3) and phosphatidyl 
inositol-3 kinase (PI3K) 12. In this study, META060 demonstrated effects on insulin sensitivity 
similar to that of rosiglitazone, prompting us to speculate whether improvement of glucose 
tolerance in META060 treated mice is mediated through a PPARγ dependent mechanism. 
However, rosiglitazone was not as effective at preventing weight gain in HFD fed mice as was 
META060, suggesting an alternative or additional mechanism of action for META060.
Results from metabolic experiments indicated that supplementation with META060 






















Figure 5. META060 improves glucose tolerance. Mice were fed a HFD or a HFD supplemented 
with 100 mg/kg/day META060 or 1 mg/kg/day rosiglitazone (Rosi). During week 5 of the diet 
intervention and after overnight fast, blood samples were collected, and glucose (A) and insulin 
(D) concentrations were determined. Oral glucose tolerance tests (OGTTs) were performed on 
fasted mice. Glucose (B) and insulin (E) concentrations were recorded at time points up to 120 min 
and areas under the curve (AUC) for glucose (C) and insulin (F) were calculated. Values are mean 
± SE (n=7-9 per group). *P<0.05 HFD vs. HFD + META060, ^P<0.05 HFD vs. HFD + Rosi. 1
79
Figure 6. Long-term META060 supplementation reduces plasma glucose and insulin 
concentrations. Fasting plasma glucose (A) and fasting insulin concentrations (C) were 
determined in mice fed a LFD, a HFD, or a HFD supplemented with 100 mg/kg/day META060 
for 14 weeks as described in Methods. OGTT was performed on fasted mice, and blood 
concentrations of glucose and insulin were determined at time points up to 120 min. Area under 
the curve (AUC) is presented for glucose (B) and insulin (D). Values are presented as mean ± SE 
(n= 5-6 per group). *P<0.05, **P<0.01, ***P<0.001.
These observations are congruent with increased insulin sensitivity and improved carbohydrate 
handling induced by META060. Differences in metabolism and weight may also be observed if 
fat intake or absorption was not consistent between treatment groups. However, the metabolic 
experiments also indicated that META060 did not affect total energy expenditure, food intake, 
nor fatty acid secretion into the feces, and thus, do not explain the reduction in weight gain of 
META060 supplemented mice. Therefore, metabolic measurements may not be sufficient to 






















Mice used in the 5-week study were slightly younger than those in the longer term 
experiment, and age may have a potential impact on physical activity, food intake, energy 
expenditure, or other metabolic processes. While it is possible that mice of different ages 
may have distinct metabolic characteristics contributing to the results we observed, the 
effects of META060 on weight gain and glucose homeostasis were consistent in both the 
short term and long term experiments. 
Results from in vitro studies in a human cecal cell line demonstrated that META060 
increases GLP-1 secretion (data not shown). Since GLP-1 is an insulin sensitizing hormone, 
this in vitro effect of META060 is consistent with in vivo effects on glucose homeostasis. 
Activation of GPR120, a G protein-coupled receptor that regulates GLP-1 secretion 17-19, 
may function as a mechanistic target for META060 dependent GLP-1 secretion, although 
further studies will be required to investigate this possibility. 
Future studies will focus on elucidating the mechanism of action underlying the effects of 
META060 on preventing weight gain in HFD fed mice and investigating whether META060 
is effective in reducing weight in obese animals. META060 reduces fasting plasma glucose 
and insulin concentrations, and further research into its activity on insulin signaling and 
hepatocyte metabolism is needed. Data presented here suggest that META060 may have 
therapeutic value as an antidiabetic or antiobesity agent, and future investigations will 
evaluate its potential clinical use.
META060 supplementation significantly reduced the amount of weight gained in mice 
on a HFD. Indirect calorimetry measurements revealed increased metabolic flexibility in 
mice, and mice demonstrated improved glucose tolerance, comparable to the effects of 
rosiglitazone treatment. We conclude that META060 has potential therapeutic value for 
managing obesity and insulin resistance.
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ABSTRACT
Inflammation plays a key role in the pathogenesis of diet-induced insulin resistance and 
type 2 diabetes. Recent studies have suggested that immunoglobulins (Ig) released by 
B-lymphocytes during the development of obesity play a key role in this pathology, although 
their mechanism of action is still unknown. Ig activate cellular responses by cross linking 
membrane receptors specific for the Fc portion of the Ig molecule (FcR). In this study, we have 
investigated whether functional FcR play a role in the development of diet-induced adipose 
tissue inflammation and diet-induced insulin resistance. To this end, FcR γ-chain-/- mice that 
are characterized by a decreased FcR-mediated activation by IgG and IgE antibodies, were 
fed a high fat diet (HFD). FcR γ-chain-/- mice gained less weight on HFD which was neither 
caused by decreased food intake nor by increased energy expenditure. However, a decreased 
postprandial response to a lipid load was observed, which suggests altered lipid absorption 
in the intestine of FcR γ-chain-/- mice. Basal glucose and insulin levels were decreased in FcR 
γ-chain-/- mice compared to WT controls and hyperinsulinemic euglycemic clamp analysis 
revealed decreased peripheral insulin resistance in FcR γ-chain-/- mice. The adipose tissue of 
FcR γ-chain-/- mice expressed lower levels of inflammatory genes and contained no crown-
like structures. Taken together, these results demonstrate that the FcR γ-chain plays a key role 
in HFD induced obesity, insulin resistance and adipose tissue inflammation and are in line 































Obesity and its related metabolic disorders such as insulin resistance and type 2 diabetes 
are associated with low-grade systemic inflammation, characterized by increased local and 
systemic production of pro inflammatory cytokines and adipokines 1, 2. 
Macrophage infiltration of expanding adipose tissue is one of the causes leading to 
increased cytokine production 3. These macrophages are classified as ‘classically’ activated 
macrophages or M1 macrophages that have increased expression of the pro inflammatory 
cytokines IL-6, TNF-α and MCP-1 4, 5. Specific pro inflammatory subsets of T-lymphocytes 
have also been found to be enriched in adipose tissue from the obese. It has been suggested 
that TH1 lymphocytes help recruit macrophages into adipose tissue and stimulate the M1 
macrophage inflammatory activation state 6, 7. 
Until recently, the role of B-lymphocytes and Ig in the development of adipose tissue 
inflammation and insulin resistance was poorly characterized. Duffaut et al. found an early 
accumulation of B-lymphocytes in adipose tissue when mice were subjected to a high fat 
diet (HFD) 8. In Pima Indians, with an inherited susceptibility for diabetes type 2, gamma 
globulin levels were positively correlated with BMI and predicted type 2 diabetes, which 
suggest that activation of the humoral immune system is involved in the development of 
insulin resistance 9. Moreover, Winer et al. have unequivocally shown that B-lymphocytes 
and antibodies play a key role in obesity associated insulin resistance. They showed that mice, 
which do not have mature B-lymphocytes, are protected against obesity-associated insulin 
resistance and in adoptive transfer experiments they demonstrated that IgG antibodies 
induce insulin resistance in the presence of a HFD 10. The underlying mechanisms of the 
antibody effector pathways are currently still unknown. In this manuscript, we have used FcR 
γ-chain-/- mice to investigate whether functional FcR could play a role in the development 
of diet-induced inflammation of adipose tissue and diet-induced insulin resistance. FcR 
γ-chain-/- mice do not express the signal transducing γ-chain of FcγRI and III and FcεRI and 
therefore these mice have a diminished activation of IgG and IgE antibody effector pathways. 
Here we show that mice deficient for FcR γ-chain are protected against diet-induced obesity, 
diet-induced adipose tissue inflammation and diet-induced insulin resistance, indicating that 
functional activating FcRs might play a role in the development of the metabolic syndrome. 
5.1 INTRODUCTION
5.2 MATERIALS AND METHODS
Animals
The generation of FcR γ-chain deficient mice in 100% C57BL/6 background has been 
described previously 11. FcR γ-chain-/- were bred at the Leiden University Medical Center, 
Leiden, The Netherlands. Wild-type (WT) control mice (C57Bl6/J background) were 
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purchased from Charles River (Maastricht, The Netherlands). Mice used in experiments 
were males, housed under standard conditions with free access to water and food. Mice 
were fed a high fat diet (HFD) for 11 weeks (45% energy derived from lard fat; D12451, 
Research Diet Services, Wijk bij Duurstede, The Netherlands) to induce obesity. Body 
weight was measured regularly during the diet intervention. All experiments were approved 
by the animal ethics committee of Leiden University Medical Center.
Plasma parameters
To determine plasma metabolite levels during week 11 of HFD feeding, tail vein blood was 
collected after an overnight fast, into capillary tubes coated with paraoxon (Sigma, St. Louis, 
MO) to prevent ongoing in vitro lipolysis. The tubes were placed on ice and centrifuged. 
Plasma triglyceride (TG), total cholesterol (TC), free fatty acid (FA), plasma phospholipids 
(PL), keton bodies, glucose and insulin levels were determined using commercially available 
kits (11488872 and 236691, Roche Molecular Biochemicals, Indianapolis, IN, NEFA-C and 
phospholipids B Wako Chemicals GmbH, Neuss, Germany, ab83390, Abcam, Cambrigde, 
UK, Instruchemie, Delfzijl, The Netherlands and Crystal Chem Inc., IL, USA, respectively). 
Determination of adipocyte size and preadipocyte differentiation capacity
Adipose tissue from the gonadal (unilateral), subcutaneous (unilateral) and visceral region 
were removed from the mice after 11 weeks of HFD and kept in PBS. The tissue was minced 
and digested in 0.5g/l collagenase in HEPES buffer (pH 7.4) with 20 g/l of dialyzed bovine 
serum albumin (BSA, fraction V, Sigma, ST Louis, USA) for 1 h at 37oC. The disaggregated 
adipose tissue was filtered through a nylon mesh with a pore size of 236 μm. For the isolation 
of mature adipocytes, cells were obtained from the surface of the filtrate and washed several 
times. Cell size was determined using an imaging processing technique which automatically 
determines fat cell sizes from microscopic pictures of isolated adipocytes (~1000 cells/fat tissue 
sample). From the measured cells the adipocyte size distribution, adipocyte number and mean 
adipocyte diameter were determined. Subsequently the volume-weighted mean adipocyte 
diameter was calculated, which is a measure of the mean adipocyte diameter corrected for the 
amount of fat that an adipocyte can store 12. For the isolation of preadipocytes, the infranatant 
of the adipose tissue filtrate was centrifuged at 200 x g for 10 min at room temperature and 
treated with erythrocyte lysis buffer. The cells were washed 2 times, re-suspended in DMEM/
NUT.MIX.F12 medium and supplemented with 10% fetal calf serum (FCS) and 100 mg/ml 
penicillin-streptomycin and inoculated into 96-well plates (12 wells/adipose tissue region) 
at a density of 40 000 cells/ml and kept at 37oC, in 5% CO2. The cells were expanded until 
confluency after which adipocyte differentiation was induced using an adipogenic medium 
containing DMEM/F12 with dexamethasone 0.1µM, 3-isobutyl-1-methylxanthine 25µM, 
insulin 17 nM, indomethacin 60µM, 10% FCS and 100 mg/ml penicillin-streptomycin. 
After 3 days, medium was changed to maintenance medium containing insulin 17 nM and 
10%FCS. After 5 more days the cells were lipid filled and intra cellular lipid accumulation was 































RNA isolation and qPCR analysis
RNA from gonadal fat of mice was isolated after 11 weeks of HFD feeding using the Nucleospin 
RNA /Protein kit (Macherey-Nagel, Düren, Germany) according to the instructions of the 
manufacturer. The quality of each mRNA sample was examined by lab-on-a-chip technology 
using Experion Stdsens analysis kit (Biorad, Hercules, CA). 600 ng of total RNA was reverse-
transcribed with iScript cDNA synthesis kit (Bio-Rad) and obtained cDNA was purified with 
Nucleospin Extract II kit (Macherey-Nagel). Real-Time PCR was carried out on the IQ5 PCR 
machine (Biorad) using the Sensimix SYBR Green RT-PCR mix (Quantace, London, UK). 
mRNA levels were normalized to mRNA levels of glyceraldehyde-3-phosphate dehydrogenase 
(Gapdh) or cyclophilin (cyclo). Primer sequences are listed in table 1. 
Immunohistochemistry
Immunohistochemistry was performed on formalin fixed and paraffin embedded sections 
of gondal adipose tissue of mice fed a HFD for 11 weeks. For detection of macrophages/
monocytes, an F4/80+ antibody (1:150) (Serotec) was used. Visualization of the complex was 
done using diaminobenzidene for 10 minutes. Negative and positive controls were included. 
Haematoxylin and Eosin (HE) stainings of sections were done using a standard protocol. 
Hyperinsulinemic Euglycemic Clamp analysis
During week 11, hyperinsulinemic euglycemic clamps were performed as described earlier 13. 
Briefly, after an overnight fast, animals were anesthetized and an infusion needle was placed 
in the tail vein. Basal glucose parameters were determined during a 60-min period, by 
infusion of D-[3-3H]glucose to achieve steady-state levels. A bolus of insulin (3 mU) was 
given and a hyperinsulinemic euglycemic clamp was started with a continuous infusion 
of insulin (5 mU/h) and D-[3-3H]glucose and a variable infusion of 12.5% D-glucose (in 
PBS) to maintain blood glucose levels at euglycemic levels. Blood samples were taken every 
Table 1. Primers used for quantitative real-time PCR analysis.




IL-6 ACCACGGCCTTCCCTACTTC CTCATTTCCACGATTTCCCAG 





F4/80, marker for macrophages; CD68, marker for macrophages; MCP-1; monocyte chemoattractant 
protein-1; IL-6, interleukin-6; IL-10, interleukin-10; ACOX1, acyl-coenzyme A oxidase 1; CPT1a, carnitine 
palmitoyltransferase 1a; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; CYCLO, cyclophilin
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5-10 min from the tip of the tail to monitor plasma glucose levels (AccuCheck). Seventy, 
eighty and ninety minutes (steady-state) after the start of the clamp, blood samples (70 
μl) were taken for determination of plasma glucose, insulin and FA concentrations using 
commercially available kits (Instruchemie, Crystal Chem Inc., and Wako Pure Chemical 
Industries). Turnover rates of glucose (μmol/min/kg) were calculated during the basal 
period and in steady-state clamp conditions as the rate of tracer infusion (dpm/min) divided 
by the plasma-specific activity of 3H-glucose (dpm/μmol). All metabolic parameters were 
expressed per kilogram of bodyweight. The hepatic glucose production (HGP) is calculated 
from the rate of disappearance (Rd) and glucose infusion rate (GIR) by the following 
equation: Rd = HGP + GIR. The Rd is measured from Steele’s equation in steady state using 
the tracer infusion rate (Vin) and plasma-specific activity (SA) of 3H-glucose (dpm/μmol) 
by the following formula: Rd = Vin/SA. 
Indirect calorimetry
During week 5 and 10 of HFD feeding groups of 8 mice were subjected to individual indirect 
calorimetry measurements using a Comprehensive Laboratory Animal Monitoring System 
(Columbus Instruments, Columbus Ohio, US). Cages were made of clear plexiglass (30 x 
10 x 9 cm (l x b x h)). A period of 24 hours prior to the start of the experiment allowed the 
acclimatization of the animals to the cages and the single housing. Experimental analysis 
started at 09:00 h and continued for 36 hours. Analyzed parameters included real time 
food and water intake, as well as meal size, frequency and duration. Oxygen consumption 
(VO2) and carbon dioxide production rates (VCO2) were measured at intervals of 7 
minutes. Respiratory exchange ratio (RER) as a measure for metabolic substrate choice was 
calculated as the ratio between VCO2 and VO2. Carbohydrate (CHO) and fat (FA) oxidation 
rates were calculated using the following formulas 14 :
CHO = ((4.585 * VCO2) – (3.226 * VO2)) * 4 / 1000
FA = ((1.695 * VO2) – (1.701 * VCO2)) * 9 /1000
Total energy expenditure was calculated from the sum of CHO and FA oxidation. 
Activity was monitored as 2-dimensional infrared beam breaks.
Liver lipids
Lipids were extracted from livers of WT and FcR γ-chain-/- fed a HFD for 11 weeks according 
to a modified protocol from Bligh and Dyer 15. Briefly, small liver pieces were homogenized 
in ice-cold methanol. After centrifugation, lipids were extracted by addition of 1800 μL 
chloroform: methanol (3:1 v/v) to 45 μL homogenate. The chloroform phase was dried and 
dissolved in 2% Triton X-100. Hepatic TG, TC and PL concentrations were measured using 
commercial kits as described earlier. Liver lipids were expressed per mg protein, which was 
































To investigate the handling of postprandial TG, mice were fed a HFD for 7 weeks. Mice were 
fasted 4 h (from 8.00 am to 12.00 pm) prior to the start of the experiment. Mice received 
an intragastric load of 200 μl olive oil (Carbonell extra virgin, Cordoba, Spain). Prior to the 
bolus and 1, 2, 4, and 8 h after bolus administration blood samples were obtained via tail 
vein bleeding for determination of plasma TG and FA as described above.
Fecal TG content
Fecal TG content was determined in feces collected during week 6 of HFD feeding. TG 
was extracted according to a modified protocol from Bligh and Dyer 15. In short, 100 mg 
of crushed feces was homogenized in methanol:chloroform (2:1). 600 μl chloroform was 
added for TG extraction and samples were centrifuged. This procedure was repeated twice 
to maximize TG extraction. After centrifugation, the chloroform layer was collected and 
chloroform was evaporated. The remaining TG pellet was dissolved in 2% Triton-x-100 
(Sigma). TG content was determined using a commercially available kit as described earlier. 
Statistical analysis
Data are presented as means ± SD. Statistical differences were calculated using the unpaired 
T-test (SPSS 16, SPSS Inc, Chicago, IL). A P-value < 0.05 was regarded statistically significant.
 
5.3 RESULTS
FcR γ-chain-/- mice are protected against HFD-induced obesity 
To induce obesity, male FcR γ-chain-/- and WT mice were fed a HFD containing 45 energy% 
fat for 11 weeks, and body weight of the mice was followed during the HFD intervention. 
FcR γ-chain-/- mice gained less body weight than WT mice (Fig. 1A). In line with this 
observation, weights of isolated fat pads were decreased in FcR-γ-chain-/- mice (gonadal 
fat -65%; P<0.001, subcutaneous fat -64%; P<0.001, visceral fat -60%; P<0.001) (Fig. 1B).
FcR γ-chain-/- adipocytes are smaller and have an improved 
differentiation capacity ex vivo
A decrease in fat pad mass can be caused by smaller adipocytes and/or by a decreased 
number of adipocytes. To investigate adipocyte morphology, adipocyte size distribution, 
volume-weighted mean adipocyte diameter and total adipocyte number were determined 
in isolated adipocytes from gonadal, subcutaneous and visceral fat pads from FcR γ-chain-/- 
and WT mice fed a HFD for 11 weeks. In FcR γ-chain-/- mice the distribution was shifted to 
the left for all three fat pads (Fig. 2A-C), indicating less hypertrophic adipocytes. Indeed, 
in FcR γ-chain-/- mice volume-weighted mean cell diameter was decreased in gonadal 
(gWAT) (-26%; P<0.001), subcutaneous (sWAT) (-29%; P<0.001) and visceral (vWAT) 
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(27%; P<0.001) white adipose tissue (Fig. 2D) compared to WT mice. In addition to smaller 
adipocytes, also a decreased number of adipocytes was found in gWAT (-27%; P<0.001) and 
sWAT (-17%; P<0.05) of FcR γ-chain-/- mice (Fig. 2E). To investigate differentiation capacity, 
isolated preadipocytes from gonadal and subcutaneous fat pads of FcR γ-chain-/- and WT 
mice were differentiated in adipogenic medium and TG accumulation was measured. An 
increased differentiation capacity was observed for gonadal preadipocytes of FcR γ-chain-/- 
mice (+147%; P<0.05) (Fig. 2F). 
FcR γ-chain-/- mice have decreased inflammation in white adipose tissue
To investigate whether functional FcR are important for white adipose tissue inflammation, 
mRNA expression of several inflammatory genes was measured in gonadal white adipose 
tissue (gWAT) of FcR γ-chain-/- and WT mice. A decreased expression of F4/80 (-46%; 
P<0.05), CD68 (-70%; P<0.001), monocyte chemotactic protein-1 (MCP-1) (-83%; 
P<0.001), interleukin 6 (IL-6) (-51%; P<0.01) and interleukin 10 (IL-10) (-58%; P<0.01) 
was found in FcR γ-chain-/- mice, which indicates decreased inflammation (Fig. 3A). 
Immunohistochemistry using an antibody that recognizes the macrophage antigen F4/80, 
showed crown like structures (CLS) in gonadal adipose tissue of WT mice, but not in 
gonadal adipose tissue of FcR-γ-chain-/- mice (Fig. 3B). 
FcR γ-chain-/- mice have decreased HFD-induced insulin resistance
To investigate whether functional FcR play a role in diet-induced insulin resistance, plasma 
glucose and insulin levels of overnight fasted FcR γ-chain-/- and WT mice that had been 
on a HFD for 11 weeks were measured. Both glucose (-28%; P<0.001) and insulin (-47%; 
P<0.001) levels were significantly decreased in FcR-γ-chain-/- mice compared to WT mice 
Figure 1. FcR γ-chain-/- mice are protected against HFD-induced obesity. Wild-type (WT) and 
FcR γ-chain-/- mice were fed a HFD for 11 weeks. Body weight of WT mice and FcR γ-chain-/- mice 
was measured at the indicated time points (A). Values are means ± SD (n= 10 per group); *P<0.05, 
**P<0.01, ***P<0.001. After 11 weeks of HFD, tissues were dissected and weight of WT and FcR 































Figure 2. FcR γ-chain-/- adipocytes are smaller and have an improved adipogenic capacity. After 
11 weeks of HFD feeding, adipocytes were isolated from gonadal (gWAT), subcutaneous (sWAT) 
and visceral (vWAT) white adipose tissues of wild-type (WT) and FcR γ-chain-/- mice. Adipocyte 
size distribution was determined (A-C). Values are means ± SD (n= 9-10 per group). Volume-
weighted mean diameter (D), total number of adipocytes (E) and adipogenic capacity (F) was 
determined. Values are means ± SD (n=9-10); *P<0.05, ***P<0.001.
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(Fig. 4A-B), suggesting that FcR-γ-chain-/- mice have decreased HFD-induced insulin 
resistance. To further investigate the insulin sensitivity, a hyperinsulinemic euglycemic 
clamp was performed. This analysis revealed a significant increase in glucose disposal 
rate in FcR γ-chain-/- mice during the hyperinsulinemic period (+20 %; P<0.05) (Fig. 4C), 
indicating that HFD-induced peripheral insulin resistance is decreased in these mice 
compared to WT controls. Insulin mediated suppression of HGP was similar in both groups 
(Fig. 4D), indicating similar hepatic insulin sensitivity after HFD. 
FcR γ-chain-/- mice have equal food intake and energy expenditure
To investigate how FcR γ-chain-/- mice are protected against diet-induced obesity indirect 
calorimetry measurements were performed in the mice during week 5 and 10 of the HFD 
intervention. Fig. 5 shows results of week 5, which were similar to the results of week 10. The 
batch of mice that was used for indirect calorimetry measurements did not differ significantly 
in body weight at week 5, only body weight gain differed significantly (body weight was 30.6 
Figure 3. FcR γ-chain-/- mice have decreased inflammation in white adipose tissue. After 
11 weeks of HFD feeding, RNA was isolated from gonadal (gWAT) white adipose tissues of 
wild-type (WT) and FcR γ-chain-/- mice. mRNA levels of F4/80, CD68, monocyte chemotactic 
protein-1 (MCP-1), interleukin 6 (IL-6) and interleukin 10 (IL-10) were determined (A). Values 
are means ± SD (n= 9-10); *P<0.05, **P<0.01, ***P<0.001. F4/80 staining in gWAT of wild-type 































± 2.2 vs. 31.3 ± 1.1, body weight gain was 3.0 ± 0.8 vs. 5.0 ± 0.8; P<0.001). Differences in 
calorimetry during week 5 could thus not be due to differences in body weight. Nocturnal 
and diurnal data were analyzed separately to distinguish between periods of low (diurnal) and 
high (nocturnal) physical activity. During the diurnal period no differences were observed in 
total energy expenditure (EE), respiratory exchange ratio (RER), absolute fatty acid (FAox) and 
absolute carbohydrate (CHox) oxidation rates both at week 5 and 10. Food intake tended to be 
lower in the FcR γ-chain-/- mice (p=0.08) during week 10, but was not different during week 5 
(Fig. 5A-E). Ambulatory physical activity during the diurnal period was not different between 
groups (data not shown) both at week 5 and 10. During the nocturnal period, ambulatory 
physical activity was higher in FcR γ-chain-/- mice, both at week 5 and 10 (week 5: +33%, 
week 10: +47%; P<0.05). This higher physical activity did not result in an increased EE in 
FcR γ-chain-/- mice. Measured food intake and EE were not different, however the average 
Figure 4. FcR γ-chain-/- mice are protected against HFD-induced insulin resistance. A second set 
of wild-type (WT) and FcR γ-chain-/- mice was fed a HFD for 11 weeks and after an overnight 
fast plasma glucose (A) and insulin levels (B) were determined. Values are means ± SD (n=8); 
***P<0.001. A hyperinsulinemic euglycemic clamp was performed in wild-type (WT) and 
FcR γ-chain-/- mice. Rate of disappearance during basal and hyperinsulinemic period (C) and 
hepatic glucose production during hyperinsulinemic period (D) were determined. Values are 
means ± SD (n=8); *P<0.05. 
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RER was increased in FcR γ-chain-/- mice, both at week 5 and 10 (week 5: +3%, week 10: +2%; 
P<0.05) which was reflected in a somewhat lower absolute FAox rate and a somewhat higher 
CHox rate (Fig. 5A-E). This higher CHox rate in FcR γ-chain
-/- mice compared to WT controls 
corresponds to the increased insulin sensitivity that was observed.
In addition, the energy balance was determined for FcR γ-chain-/- and WT mice by 
calculating [food intake (kcal/24h)] – [energy expenditure (kcal/24h)]. No significant 
Figure 5. FcR γ-chain-/- mice have equal 
food intake and energy expenditure. The 
second set of wild-type (WT) and FcR 
γ-chain-/- mice was subjected to indirect 
calorimetry measurements during week 
5 of HFD intervention. Food intake (FI) 
(A), energy expenditure (B), respiratory 
exchange rates (C), fat oxidation (D) 
and carbohydrate oxidation levels (E) 
































differences in energy balance were observed, both during week 5 and 10 (week 5: +8.9 ± 1.8 
vs. +10.0 ± 5.5, week 10: +3.4 ± 1.8 vs. +4.4 ± 3.8). 
FcR γ-chain-/- mice have decreased plasma lipid levels and decreased liver 
lipid levels
To further unravel the mechanisms underlying the decreased adiposity of the FcR γ-chain-
/- mice, plasma lipid parameters were determined during week 11 of HFD feeding. Plasma 
TG, TC and PL levels were significantly decreased in FcR γ-chain-/- mice (-26%; P<0.05, 
-39% and -24 %; P<0.001) (Table 2). In addition liver lipids were measured, demonstrating 
decreased liver TG content in FcR γ-chain-/- mice (-60%; P<0.001) (Fig. 6A). mRNA levels of 
acyl-Coenzyme A oxidase 1 (Acox1) and carnitine palmitoyltransferase 1a (Cpt1a), 2 genes 
involved in β-oxidation, were decreased in FcR γ-chain-/- mice (-66%; P<0.001 and -59%; 
P<0.01) (Fig. 6B). Furthermore, keton bodies in plasma were measured during week 9 and 
11 of the HFD intervention in 2 batches of mice. Equal or decreased levels of keton bodies 
were observed, respectively (1.06 ± 0.25 versus 1.02 ± 0.28 and 0.90 ± 0.27 versus 1.23 ± 0.14; 
P<0.01). Together these results indicate decreased β-oxidation in FcR γ-chain-/- mice. 
FcR γ-chain-/- mice have decreased postprandial response
Decreased adiposity in FcR γ-chain-/- mice might also be caused by absorption problems. To 
investigate this hypothesis, FcR γ-chain-/- and WT mice were given an oral bolus of 200 μl 
olive oil after 7 weeks of HFD and plasma TG levels were monitored in time. FcR γ-chain-/- 
mice had a decreased postprandial response compared to WT mice (Fig. 7A). However, no 
Figure 6. FcR γ-chain-/- mice have decreased plasma lipid levels and decreased liver lipid levels. 
After 11 weeks of HFD, liver was dissected of wild-type (WT) and FcR γ-chain-/- mice and liver 
lipids were determined (A). Values are means ± SD (n=5); ***P<0.001. RNA was isolated from 
WT and FcR γ-chain-/- livers and mRNA levels of acyl-Coenzyme A oxidase 1 (Acox1) and 
carnitine palmitoyltransferase 1a (Cpt1a) were measured (B). Values are means ± SD (n=9-10); 
**P<0.01, ***P<0.001.
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Figure 7. FcR γ-chain-/- mice have decreased postprandial response. After 7 weeks of HFD, the 
postprandial response triglyceride (TG) was determined in a third set of wild-type (WT) and 
FcR γ-chain-/- mice (A). Values are means ± SD (n=9); *P<0.05, **P<0.01, ***P<0.001. During 
week 6 of HFD intervention feces was collected of these mice and TG content was determined in 
fecal samples of WT and FcR γ-chain-/- mice (B). Values are means ± SD (n=7-9). 
differences in fecal TG content were observed (Fig. 7B). These data indicate that intestinal 
lipid absorption kinetics are affected in FcR γ-chain-/- mice.
Table 2. FcR γ-chain-/- mice have decreased plasma lipid levels on high fat diet.
WT FcR γ-chain-/-
TG (mM) 1.10 ± 0.30 0.81 ± 0.21*
TC (mM) 4.23 ± 0.30 2.56 ± 0.40***
PL (mM) 2.99 ± 0.36 2.26 ± 0.38***
FA (mM) 1.08 ± 0.22 1.21 ± 0.24
Plasma was obtained from overnight fasted mice during week 11 of high fat diet intervention (n=10). 
Plasma triglycerides (TG), total cholesterol (TC), phospholipids (PL) and free fatty acids (FA) were 
measured. Values are means ± SD. *P<0.05, ***P<0.001.
5.4 DISCUSSION
The study presented here is to our knowledge the first to indicate that FcR associated antibody 
effector pathways are involved in the development of diet-induced insulin resistance. We 
show that after a HFD, FcR γ-chain-/- mice become less obese and develop less adipose 
tissue inflammation and peripheral insulin resistance compared to WT controls. As the 
FcR γ-chain is crucial for full activation of IgG and IgE antibody effector pathways, our 































these processes. Our results are in line with a role of Ig in the development of HFD-induced 
insulin resistance, which has recently been shown by Winer et al. 10. 
The FcR γ-chain-/- mice showed a reduced body weight gain and decreased adipocyte size as 
compared to HFD-fed WT mice. Since body weight and adipocyte size per se are determinants 
of insulin sensitivity, these effects can explain at least part of the observed decreased HFD-
induced insulin resistance. However, the calorimetry measurements demonstrated a higher 
CHox rate in FcR γ-chain
-/- mice during week 5 when the FcR γ-chain-/- and WT mice did not 
differ in body weight. As a high CHox rate corresponds to increased insulin sensitivity, these 
data may suggest that the Fc γ-chain per se plays a role in diet-induced insulin resistance 
and is not only a consequence of the effects on body weight. In the study of Winer et al., 
B-lymphocyte deficient mice showed improved glucose tolerance and insulin sensitivity 
compared to HFD-fed WT mice, although they did not differ from WT mice in weight gain 
nor adipocyte size upon HFD feeding. Their study suggests that B-lymphocyte derived Ig are 
responsible for a body weight-independent effect on HFD-induced insulin resistance 10. In 
another recent study using B-lymphocyte deficient mice on BalbC background (BcKO mice), 
body fat stores were assessed after a HFD and the BcKO mice did show reduced inguinal and 
epididymal fat stores compared to their heterozygous littermate controls 16. 
The fact that FcR γ-chain-/- mice are relatively protected against HFD-induced obesity 
cannot be explained by differences in food intake nor energy expenditure. However, intestinal 
lipid absorption may be affected in FcR γ-chain-/- mice as indicated by a decreased postprandial 
response to an olive oil load. In line with a reduction of the intestinal lipid flux, circulating plasma 
TG and liver TG were both decreased and genes involved in β-oxidation were also decreased. 
Despite the reduced postprandial TG response, fecal fat secretion was not different from 
WT mice. Combined, these observations may indicate that the lipids that were not absorbed 
postprandially as plasma TG in the FcR γ-chain-/- mice, were still being metabolized in the 
intestine, most likely by the intestinal microbiota. Since intestinal microbiota are predominantly 
anaerobic, energy expended via this pathway will not be measured by gas-based calorimetry 
equipment. Although the TG/FA breakdown products from the intestinal microbiota (such as 
short chain FA) will be absorbed and used as fuel, the net energy output will be much lower as 
the microbial conversion reactions cost a lot of energy. This loss of energy may also contribute 
to the reduced body weight gain in HFD-fed FcR γ-chain-/- mice.
Recently, it was found that in the absence of IgA, the major antibody class in the gut, and 
in the presence of microbiota, the intestinal epithelium down regulates its metabolic functions 
and up regulates its immune functions, which ultimately results in lipid malabsorption. These 
effects were also observed in B-lymphocyte deficient mice. Moreover, duodenal samples of 
immunodeficient humans display a down regulation of metabolic genes and an up regulation 
of genes involved in immunity in intestinal epithelium 16. The TG absorption problems 
found in the FcR γ-chain-/- mice, which also represent an immune-compromised model, are 
completely in line with these observations. However, we do not know whether IgA is involved 
in the observed phenotype of the FcR γ-chain-/- mice, since in mice the FcR for IgA – i.e FcαR- 
has never been identified, in contrast to in humans. Humans express a γ-chain associated high 
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affinity receptor for IgA, FcαRI (CD89). However, this FcαRI, expressed on myeloid cells such 
as macrophages, neutrophils and eosinophils, has never been found in mice 17. 
Besides its association with different FcR, the FcR γ-chain is also associated with several 
receptors involved in innate immunity including NKR-P1C, PIR-A and IL3R. NKR-P1C is 
expressed on natural killer cells and mediates cytotoxicity against tumor cells 18. The paired 
immunoglobulin like receptor-A (PIR-A), which is present on monocytes and macrophages, 
dendritic cells, mast cells and certain B lymphocytes subsets expressing natural antibodies, is 
able to activate these cells upon interaction with major histocompatibility complex (MHC) 
class 1 molecules 19. Additionally, the γ-chain is a constitutive component of IL-3R and 
is necessary for IL-3-induced production of IL-4 by basophils 20. Together these findings 
indicate that besides a signaling role in the antibody mediated effector mechanisms, the 
FcR γ-chain plays also an important role in innate immunity, which could contribute to the 
metabolic phenotype of the FcR γ-chain-/- mice that we observed. 
However, we postulate that the FcR γ-chain-/- mice is a suitable model to study antibody 
effector mechanisms despite its association to other receptor types. In case FcR are involved in 
HFD-induced obesity and insulin resistance, the FcR γ-chain-/- mice should show a phenotype. 
Our experiments indicate that FcR γ-chain-/- mice indeed have a phenotype, which is a first 
indication for a major role for FcR mediated Ig effector pathways in HFD-induced obesity and 
insulin resistance and therefore they provide multiple avenues for future studies.
In conclusion, our data provide direct evidence for a role of the FcR γ-chain in HFD-
induced obesity and insulin resistance. Although, we cannot exclude that non-FcR mediated 
mechanisms are responsible for this effect, our data suggests a major role for FcR mediated 
Ig effector pathways in HFD obesity and insulin resistance Our data also clearly indicate 
that FcR γ-chain mediated pathways are important in multiple tissues involved in HFD-
induced pathology, including adipose tissue and the intestine.
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The metabolic syndrome, a multi-component condition including obesity, insulin resistance, 
dyslipidemia and hypertension, is associated with an increased risk for cardiovascular 
diseases and diabetes. The prevalence of the metabolic syndrome, currently around 30%, 
is rising worldwide and this rise parallels the increase in the prevalence of overweight and 
obesity. In 2009, 47% of all Dutch adults had overweight of which 12% were obese 1.
Chronic low-grade inflammation is thought to function as the link between the 
various components of the metabolic syndrome and the development of the associated 
pathologies. Disturbances in triglyceride (TG) and fatty acid (FA) metabolism can drive the 
inflammatory response and vice versa, the inflammatory response can drive disturbances 
in TG/FA metabolism. However, the mechanisms underlying these interactions between 
TG/FA metabolism and inflammation remain to be fully understood. In this thesis, we have 
investigated how modulation of TG/FA metabolism and inflammatory pathways interact in 
the development of obesity and insulin resistance, which are both primary risk factors for 
the development of type 2 diabetes. 
6.1 ROLE OF FA TRANSPORT IN ADIPOSE TISSUE DEVELOPMENT AND INFLAMMATION
Adipose tissue is the first visually affected organ in the development of obesity and the 
metabolic syndrome. Excessive calories are stored in adipose tissue as TG. Energy storage 
in adipocytes is partly regulated by FA transporters in adipocytes that facilitate FA entry. 
In chapter 2 we found that the FA transporter CD36 is important for adipocyte recruitment 
and adipocyte functionality. CD36-/- mice become less obese on high fat diet (HFD), although 
their body weight is still increased compared to mice fed a normal chow diet. Adipose tissue 
of CD36-/- mice has some healthy aspects compared to adipose tissue of wild-type (WT) mice, 
since we found that the adipocytes of CD36-/- mice are more insulin sensitive and the adipose 
tissue of CD36-/- mice is less inflamed. Nevertheless, the adipose tissue of these animals should 
be considered as dysfunctional. The adipocytes of CD36-/- mice cannot store surplus FA and 
also the recruitment of new adipocytes is impaired. As a result the FA are trans located to the 
liver and stored ectopically, which results in hepatic insulin resistance. 
Differences in storage capacity of adipose tissue are important in the development of the 
metabolic syndrome. Human cohort studies indicate that there are individuals who are obese 
but seem to remain metabolically healthy. These individuals have a healthy lipid profile, e.g. 
lower TG, higher high density lipoprotein (HDL) cholesterol, lower fasting glucose and insulin 
concentrations and better glucose tolerance compared to unhealthy obese individuals, despite a 
similar level of total body fat 2. Several studies have shown that the expandability of subcutaneous 
fat is critical for maintaining healthy obesity 3. If this capacity to expand is large, an individual 
is more likely to remain healthy, even when obese. If the expandability of subcutaneous fat is 
low, excess fat is likely to be stored intra-abdominally (in visceral fat) or in non-adipose tissues 
(ectopic fat deposition), which is associated with an adverse metabolic profile 
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Different factors could play a role in the capacity of the subcutaneous fat to expand. Fat 
mass, fat distribution and adipocyte numbers are for a large part genetically determined. 
Twin and population studies have indicated that 25-70% of the variability in these traits 
can be explained by genetics. For example, variation in the LPL gene and mutations in the 
β3-adrenergic receptor gene have been associated with visceral obesity 4. 
Additional important factors that could play a role in maintaining healthy adipose 
tissue are nutrition and exercise. A controlled-feeding trial demonstrated that consumption 
of a diet enriched in saturated FA (SFA) led to an increased expression of genes involved 
in inflammatory processes, while a diet enriched in monounsaturated FA (MUFA) led to 
decreased expression of inflammatory genes in adipose tissue of overweight subjects 5. 
Thus, the type of dietary FA seems to affect inflammation in adipose tissue. 
Physical activity also likely contributes to healthy obesity. It has been found that 
active obese men (fat fit men) have increased HDL cholesterol levels, decreased TG levels, 
decreased alanine aminotransferase (ALT) levels (which is a marker for liver damage), and 
improved insulin sensitivity, as measured by HOMA-index, compared to unfit obese men 
(fat unfit men). In addition, visceral fat and liver fat were decreased in fat fit men compared 
to fat unfit men. It has been postulated that men who are fit and fat have a greater capacity 
to store fat in subcutaneous adipose tissue 6. 
If the expandability capacity of subcutaneous adipose tissue is decreased, excessive 
FA are more likely to be stored as visceral fat or in non-adipose tissues as ectopic fat. In 
its most extreme form this is illustrated by patients with lipodystrophy, who despite a 
normal BMI display features of the metabolic syndrome such as insulin resistance and 
hypertriglyceridemia. These patients have genetic defects in the development of adipose 
tissue and are characterized by extremely fatty livers. Insight in the genetics of lipodystrophy 
provides direct insight in adipose tissue development and function, and contributes to a 
better understanding of the onset of the pathology associated with the metabolic syndrome 7. 
A less extreme form of lipodystrophy may affect individuals who despite a normal 
weight and BMI, display signs of insulin resistance and dyslipidemia. These individuals 
have been identified as metabolically obese normal weight (MONW) individuals 8. MONW 
individuals are characterized by an increased visceral fat mass, which is associated with 
decreased insulin sensitivity 9. Seppala-Linderoos et al. have found increased hepatic TG 
content in nonobese men who have high levels of plasma insulin and TG 10. 
Physical inactivity may be an important characteristic of MONW individuals 11. An 
inverse relationship between maximal oxygen uptake (VO2max) and insulin insensitivity 
has been shown 12. Several studies have demonstrated that regular exercise, either in 
combination with a healthy diet ameliorates metabolic abnormalities and reverses adverse 
fat distribution 13-16. These studies illustrate the necessity of some basal level of physical 












Adipose tissue expansion and obesity are associated with the development of low-grade 
inflammation 17. Expansion of adipose tissue is beyond a certain point physically limited by 
nutrient and oxygen supply. The subsequent hypoxia, endoplasmatic reticulum stress and 
apoptosis may lead to infiltration of immune cells into adipose tissue such as macrophages 18, 
activated T-lymphocytes 19 20-22 and activated B-lymphocytes 20, 23. Under normal physiological 
conditions, this response is self-limited and geared towards a new metabolic and 
inflammatory equilibrium. However, under conditions of chronic overnutrition, the 
low-grade inflammation can also become chronic. This chronic low-grade inflammation 
has been termed metabolic inflammation, since it is hypothesized that this inflammation is 
triggered by a surplus of nutrients. Metabolic inflammation is characterized by increased 
plasma levels of pro inflammatory cytokines, insulin resistance and a deregulation of TG/FA 
metabolism 24. Inflammation, insulin resistance, and deregulation of TG/FA metabolism are 
part of a vicious cycle that drives the progression of diabetes and cardiovascular diseases. 
Inflammation itself can directly affect lipoprotein metabolism as illustrated by the 
observation that patients with acute infections have elevated VLDL TG levels 25. In addition, 
administration of lipopolysaccharide (LPS), a strongly pro inflammatory component of 
the cell wall of Gram-negative bacteria, and cytokines produce hypertriglyceridemia 26. 
Conversely, disturbances of lipid metabolism can also produce a pro-inflammatory state. 
SFA can stimulate inflammatory pathways via Toll Like Receptor (TLR) 4 27 or via increased 
reactive oxygen species (ROS) production. Recently it was found that SFA-induced ROS 
can activate the inflammasome complex, which results in increased release of the pro 
inflammatory cytokine IL-1β 28. 
 In chapter 3 and 4 of this thesis, we have investigated the effect of anti-inflammatory 
compounds on TG metabolism (chapter 3) and glucose tolerance (chapter 4). In chapter 3 
we show that high-dose aspirin, which decreases total hepatic NF-κB activity, also reduces 
hepatic VLDL-TG production in HFD-fed mice, thereby reducing the plasma TG levels of 
hypertriglyceridemic mice. In chapter 4 we showed that a botanical agent that has shown 
anti-inflammatory activity in vitro, was able to reduce body weight gain and diminish 
glucose intolerance in mice fed a HFD. Anti-inflammatory agents might therefore be 
interesting to treat symptoms of the metabolic syndrome. 
High-dose aspirin has been shown to improve insulin sensitivity in obese type 2 
diabetics 29. In this study also a reduction of plasma TG was observed. Since prolonged 
use of high-dose aspirin can lead to gastrointestinal bleedings, clinical trials are being 
performed with salsalate, another anti-inflammatory agent based on the active compound 
salicylic acid, with fewer side effects than aspirin. Recently, high-dose salsalate treatment 
has shown to improve glycemic control, to decrease CRP levels and to decrease TG levels 
in type 2 diabetic patients 30. Botanical compounds like META060 that we have tested in 
chapter 4 are anticipated to have even fewer side effects. 
6.2 ROLE OF INFLAMMATION IN TRIGLYCERIDE METABOLISM AND INSULIN RESISTANCE
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Even when unwanted potential side effects of anti-inflammatory compounds can be 
avoided, one could argue that reducing the inflammatory response in itself may be dangerous, 
since the capacity to destroy potential pathogens is also diminished. In this respect, adverse 
effects of anti-TNF-α have been reported. Treatment with TNF-α blockers has long been 
established for patients with rheumatoid arthritis (RA) and Crohn’s disease. Because of 
the tight association between inflammation and insulin resistance and the positive effects 
on glucose and insulin levels in patients with RA 31, 32 anti-TNF-α agents have been tested 
in individuals with the metabolic syndrome. Etanercept, an anti-TNF-α agent, was found 
to improve fasting glucose levels in individuals with the metabolic syndrome 33. Extensive 
use of anti-TNF-α agents in treatment of the metabolic syndrome was however not 
recommended, since increased risk of infection has been reported in patients with RA and 
Crohn’s disease 34. A more promising anti-inflammatory agent is Anakinra. Anakinra is an 
IL-1 receptor antagonist (IL-1ra) that counterbalances the pro inflammatory cytokine IL-1β. 
Administration of Anakinra resulted in improved glycemic control due to improved β-cell 
function in type 2 diabetic patients, although insulin sensitivity was unchanged 35. In line with 
these results it was shown that in non-diabetic subjects treatment with IL-1ra improved β-cell 
function, but insulin sensitivity remained similar 36. In contrast to treatment with anti-TNF-α, 
no significant increase in incidence of infection in RA patients treated with Anakinra have 
been reported 37. Also for salsalate, there are no known effects for increased risk of infection 30. 
Although anti-inflammatory agents are thus promising in treating insulin resistance 
and hypertriglyceridemia, a large randomized clinical trial has shown that intensive 
lifestyle intervention, i.e. weight loss due to caloric restriction and physical exercise, is 
also able to reduce inflammation as demonstrated by lower CRP levels 38. In comparison 
with metformin, intensive lifestyle intervention was able to prevent diabetes to a greater 
extent in patients with impaired glucose tolerance 39. Thus, anti-inflammatory agents may 
be useful to reduce the inflammatory burden on the short term, whereas intensive lifestyle 
intervention and maintenance of this novel life style could do so on the long term.
6.3 ROLE OF THE ADAPTIVE IMMUNE SYSTEM  IN METABOLIC INFLAMMATION 
Recent studies have shown that the adaptive immune system plays a clear role in metabolic 
inflammation. Increased amounts of TH1 and CD8
+ T-lymphocytes in adipose tissues of obese 
individuals have been reported 21, 22. Yang et al. found that T-lymphocytes that reside in adipose 
tissue of diet-induced obese mice have a restricted T Cell Receptor (TCR) profile 40, which suggest 
that there is ongoing antigen exposure eliciting an active adaptive immune response. Recently, it 
was found that transfer of IgG antibodies of diet-induced obese mice to B-lymphocyte deficient 
mice induces adipose tissue inflammation and insulin resistance in these mice 41.
In chapter 5, we revealed that functional activating Fc receptors (FcR) likely play a role in 
diet-induced obesity and associated diet-induced adipose tissue inflammation and insulin 












many hematopoietic cells, including macrophages. Cross-linking of these receptors activates 
cellular responses that are important for inflammation and immunity. The observation that 
functional FcR are likely involved in diet-induced obesity and inflammation suggest that 
antibodies are able to elicit a pro inflammatory response via cross-linking with FcR, which 
subsequently contributes to metabolic abnormalities seen in obese subjects. 
Currently it is unclear against which antigens these antibodies are directed. Also it is unclear 
how B-lymphocytes acquire antigens. It could be that antigens arise from stressed apoptotic 
adipocytes, since it was observed that IgG antibodies localize with crown-like structures 41. 
Invariant natural killer T (iNKT) cells may also play a role in B-lymphocyte activation. iNKT 
cells react to lipid stimuli and are able to activate antibody production by B-lymphocytes 42. 
Recently it was found that mice fed a HFD have an increased amount of activated iNKT cells. It 
was also discovered that iNTK cell-deficiency protects against diet-induced insulin resistance 
and adipose tissue inflammation. Since similar results were obtained with db/db mice fed a 
chow diet, it is unlikely that exogenous lipids activate iNKT cells. Instead, the authors suggest 
that dyslipidemia in obesity results in iNKT cells loaded with self-lipids. These lipids could 
be presented to iNKT cells by antigen presenting cells such as macrophages 43. The increased 
amount of activated iNKT cells in obese mice may contribute to an increased B-lymphocyte 
activation, which subsequently leads to adverse metabolic effects. 
The observation that the adaptive immune system is involved in the onset of insulin 
resistance offers new therapeutic possibilities. HFD-fed mice treated with CD3 specific 
antibody, which inactivates pro inflammatory TH1 lymphocytes and selectively increases Treg 
lymphocytes, showed improved glucose tolerance 22. In addition, deletion of B-lymphocytes 
with CD20 specific monoclonal antibody in HFD-fed mice also resulted in improved glucose 
tolerance 41. More B-lymphocyte or antibody modulating agents such as inhibitors against 
CD19 and CD22 are available for usage in humans. Specific deletion of iNKT cells by an iNKT 
cell-specific antibody in individuals prone to develop the metabolic syndrome could also be 
protective in these individuals. However, just as mentioned in the previous section on anti-
inflammatory compounds, a possible side effect of interference in the adaptive immune system 
may be enhanced susceptibility to invading pathogens. Therefore a target-tissue approach 
might be important. For instance, agents that specifically target the pro inflammatory response 
in adipose tissue would attenuate adipose tissue inflammation and associated insulin resistance, 
without disrupting other immune functions in the body of an individual. 
6.4 ROLE OF THE GUT IN METABOLIC INFLAMMATION
Recently, attention has been drawn to the role of microbiota and epithelial barrier function of 
the gut in metabolic inflammation. It was found that innate immune suppression, by deletion 
of components of the inflammasome, can lead to altered gut microbiota, which results in 
transfer of bacterial products to the portal circulation where TLR 4 and 9 are activated, which 
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ultimately leads to enhanced pro inflammatory signaling 44. Another study showed that 
gut microbiota per se can induce obesity and insulin resistance in mice that are genetically 
protected against obesity and insulin resistance (the mice used in this study were TLR 2 
deficient) by increasing the gut permeability, which leads to increased LPS absorption 45. 
We observed that both CD36-deficient mice as well as FcR γ-chain deficient mice have 
increased intestinal length (data not shown), indicating that alterations in lipid metabolism and 
inflammation are associated with alterations in the intestine. Human and mice studies have 
indicated that there is an association between immune suppression and lipid malabsorption 46. 
Since microbiota and the epithelial barrier function can be changed by diet, the role of 
altered microbiota/epithelial barrier function is another factor that should be taken into 
account when studying the onset of the metabolic syndrome. Already, a few years ago it was 
shown that weight loss by following a fat or carbohydrate restricted low calorie diet, could 
induce a shift in bacterial phyla of obese people 47. Recently, it was found by Everard et al. 
that the botanical compound META060 that we have used in chapter 4 increased expression 
of two key intestinal tight junction proteins, thereby reducing the gut permeability 48. 
Prebiotics, non-digestible nutrients such as dietary fibre and frutan, are also able to change 
gut microbiota. In obese individuals, fructan administration has shown a positive effect on 
BMI. Additional studies have demonstrated favorable effects of fructans on gastro-intestinal 
peptides such as PYY and GLP-1, which may contribute to the positive effects of fructan. 
Which gut microbial species are responsible for these positive effects is currently unknown, 
since many are changed upon treatment with prebiotica 49. 
6.5 CONCLUDING REMARKS
The increasing prevalence of the metabolic syndrome world-wide urges the development 
of new drugs and therapies that reduce the progress of metabolic disturbances such as 
hypertriglyceridemia and insulin resistance. In the last decades it has become clear that 
FA metabolites and chronic inflammation are involved in the pathology of the metabolic 
syndrome. The epithelial barrier function of the gut also has to be taken into account when 
studying the metabolic syndrome. For the development of new drugs and therapies it is 
essential to evaluate how FA metabolites and inflammatory pathways contribute to the 
development of hypertriglyceridemia and insulin resistance. In this thesis we showed that 
CD36 plays a role in proper storage of FA in mature adipocytes as well as in recruitment of new 
adipocytes, thereby reducing ectopic fat deposition. Also, we identified that FcR antibody 
effector pathways may be involved in the development of obesity and insulin resistance, 
which suggest new diagnostic and therapeutic possibilities for managing the metabolic 
syndrome. Furthermore we found that inhibition of inflammatory pathways reduces 
hypertriglyceridemia and insulin resistance. Although anti-inflammatory agents might be 












response is necessary for destroying pathogens. Therefore, lifestyle-changing programs that 
help patients with improving (and maintaining) their dietary habits and adapting to a more 
physical active lifestyle deserve attention as well, since these interventions have proven to 
be successful in managing the metabolic syndrome. 
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The metabolic syndrome is a multi-component condition that includes obesity 
hypertriglyceridemia and insulin resistance. The prevalence of the metabolic syndrome 
is rising world-wide and is associated with an increased risk for the development of 
cardiovascular diseases and type 2 diabetes. In the past decades it has been discovered 
that obese persons have slightly elevated markers of inflammation in their plasma. This 
low-grade chronic inflammation, also called metabolic inflammation, is hypothesized to 
function as the link between the various components of the metabolic syndrome. In this 
thesis, we have evaluated how alterations in triglyceride (TG) and fatty acid (FA) metabolism 
and inflammatory pathways interact in the development of obesity and insulin resistance, 
which are both primary risk factors for the development of type 2 diabetes. 
Adipose tissue plays a central role in the development of the metabolic syndrome. 
Under healthy conditions, excess calories are stored in adipose tissue. When energy intake 
continues to exceed energy expenditure, the adipose tissue needs to expand in order to store 
these excess calories. When the capacity of the adipose tissue to expand is not yet reached, 
the excessive calories are mainly stored as fat. When the storage capacity of adipose tissue 
is reached, the excessive calories may be stored in non-adipose tissue (ectopic fat). This 
pathophysiological condition is associated with an increased risk for insulin resistance. 
One of the functions of the scavenger receptor CD36 is to facilitate the entry of FA into 
a variety of cells, including adipocytes. In chapter 2 we have investigated the role of CD36 in 
preadipocyte recruitment and adipocyte functionality in gonadal, visceral and subcutaneous 
adipose tissue. For this purpose, we used CD36-deficient mice (CD36-/- mice) that were 
given a high fat diet (HFD). The CD36-/- mice showed diminished uptake of TG-rich particle 
derived FA in adipose tissue. As a consequence, gonadal, visceral and subcutaneous fat pads 
were smaller in these animals. A reduction in fat pad size can be caused by a reduction in size 
or a reduction in total number of adipocytes. We showed that adipocyte size was reduced 
in gonadal, visceral and subcutaneous fat pads of CD36-/- mice. In addition, a reduced total 
number of gondadal adipocytes was observed in CD36-/- mice. This reduction was caused 
by a decreased number of very small adipocytes (<50 µm). Our data suggest that CD36-
deficiency reduces the capacity of preadipocytes to become adipocytes, since we measured a 
reduced number of very small adipocytes but an increased pool of preadipocytes in gonadal 
fat of CD36-/- mice. This deficiency in preadipocyte recruitment was not due to an intrinsic 
developmental defect, since in vitro differentiation experiments did not reveal a reduction 
in intra cellular lipid accumulation. Smaller adipocytes as observed in CD36-/- mice would 
be expected to have a decreased rate of lipolysis. Surprisingly, lipolysis was increased in 
adipocytes from CD36-/- mice. Altogether our results indicate that CD36 plays an important 
role in adipose tissue functionality both by regulating FA uptake and release. This in turn 
has an impact on the distribution of fat to adipose and non-adipose tissues. The reduced 
uptake of FA in adipose tissue was paralleled by an increased uptake of FA in the liver. We 
demonstrated that the fatty liver of CD36-/- mice was more insulin resistant. 
Expansion of adipose tissue is often accompanied by infiltration of immune cells 
into the adipose tissue. Therefore, adipose tissue is thought to play a central role in the 
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onset of metabolic inflammation, although in other organs such as the liver and muscle 
inflammation in response to lipid accumulation can be observed as well. Immune cells 
are able to secrete cytokines that elicit a pro inflammatory response that is associated with 
the development of insulin resistance and hypertriglyceridemia. Inflammation, insulin 
resistance, and deregulation of TG/FA metabolism are part of a vicious cycle that drives the 
progression of diabetes and cardiovascular diseases. 
Systemic inflammation induces an increase in plasma TG levels. Aspirin treatment in 
type 2 diabetes patients resulted in a decrease in plasma TG. In chapter 3 we have aimed to 
investigate the mechanism by which aspirin reduced hypertriglyceridemia. Therefore we fed 
human apolipoprotein CI (apoCI)-expressing mice (APOC1), a mouse model with elevated 
plasma TG levels, as well as normolipidemic wild-type (WT) mice a HFD and treated them 
with aspirin. Aspirin treatment reduced hepatic NF-κB activity in HFD-fed APOC1 and WT 
mice and in addition, aspirin decreased plasma TG levels in hypertriglyceridemic APOC1 
mice. This TG-lowering effect could not be explained by enhanced VLDL-TG clearance, 
but aspirin selectively reduced hepatic VLDL-TG production in both APOC1 and WT 
mice without affecting VLDL-apo B production. Aspirin did not alter hepatic expression 
of genes involved in FA oxidation, lipogenesis and VLDL production, but decreased the 
incorporation of plasma-derived FA by the liver into VLDL-TG, which was independent of 
hepatic expression of genes involved in FA uptake and transport. We concluded that aspirin 
improves hypertriglyceridemia by decreasing VLDL-TG production without affecting 
VLDL particle production. Our results suggest that inhibition of inflammatory pathways by 
aspirin could be an interesting target for the treatment of hyptertriglyceridemia. 
In chapter 4 we have investigated the effects of a botanical component META060 on body 
weight development and insulin sensitivity. META060 has shown anti-inflammatory activity 
in vitro. Compared to WT mice fed a HFD, mice fed a HFD supplemented with META060 
were protected against the development of diet-induced obesity. Moreover the mice that 
received META060 had improved glucose tolerance, indicating that this component has 
potential therapeutic value in the management of obesity and insulin resistance. 
The adaptive immune system plays a clear role in metabolic inflammation. Increased 
amounts of specific pro inflammatory subtypes of T-lymphocytes and activated 
B-lymphocytes have been found in the adipose tissue of obese subjects. Furthermore, mice 
fed a HFD have a restricted T Cell Receptor profile. In addition, antibodies obtained from 
diet-induced obese mice are able to elicit adipose tissue inflammation and insulin resistance 
in B-lymphocyte deficient mice. Altogether this indicates that the adaptive immune system 
is important in metabolic inflammation and its associated pathologies. 
Antibody molecules activate cellular responses that are important for inflammation 
by cross-linking their Fc portion with specific membrane receptors (FcR). In chapter 5 
we have investigated whether functional FcR could be important in the development of 
diet-induced adipose tissue inflammation and diet-induced insulin resistance by subjecting 
FcR γ-chain-/- mice that miss the γ-chain that is needed for proper signal transduction 







reduced diet-induced obesity, diminished adipose tissue inflammation and less peripheral 
insulin resistance, indicating that functional FcR are likely to play a role in the development 
of metabolic inflammation. 
Taken together, the studies described in this thesis contribute to the understanding 
that functionality of adipose tissue and metabolic inflammation are important factors 
in the development of diet-induced obesity and insulin resistance. We show that CD36 
is important for proper adipocyte functioning, thereby reducing the risk of ectopic fat 
storage in the liver. We have identified that FcR antibody effector pathways may be involved 
in the development of obesity and insulin resistance, which suggest new diagnostic and 
therapeutic possibilities for managing the metabolic syndrome. Furthermore we found that 
anti-inflammatory agents reduce hypertriglyceridemia and insulin resistance.
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Het aantal mensen met het metabool syndroom neemt werelwijd al enkele tientallen jaren 
toe. Metabool syndroom is de aanduiding voor een verzameling van een verschillend aantal 
verstoringen in de stofwisseling, zoals hypertriglyceridemie (een verhoogd gehalte aan vet 
in het bloed) en insulineresistentie (een verminderde gevoeligheid voor insuline). Deze 
verstoringen in de stofwisseling leiden tot een verhoogd risico op het ontwikkelen van hart- 
en vaatziekten en type 2 diabetes. Er is sprake van het metabool syndroom wanneer 3 of meer 
van de volgende risicofactoren tegelijkertijd aanwezig zijn: veel vet in de buikstreek, een hoge 
bloeddruk, een verhoogd nuchter bloedsuikergehalte, een verhoogd gehalte aan vet in het 
bloed of een verlaagd HDL-cholesterol gehalte in het bloed. Zwaarlijvigheid, oftewel obesitas, 
is een belangrijke component in het metabool syndroom. Het steeds vaker voorkomen van 
overgewicht en obesitas leidt dan ook tot een toename van het metabool syndroom. 
Om te bepalen of er sprake is van overgewicht of obesitas, wordt er gebruik gemaakt van 
de Body Mass Index (BMI). Deze wordt als volgt berekend: het lichaamsgewicht in kilogram, 
gedeeld door de lichaamslengte in meter in het kwadraat (kg/m2). Een BMI tussen 18,5 en 
25 wordt beschouwd als gezond, een BMI van meer dan 25 wordt beschouwd als te zwaar 
(overgewicht) en een BMI van meer dan 30 wordt beschouwd als obesitas. Overmatige inname 
van calorieën ten opzicht van de hoeveelheid verbrandde calorieën is een van de belangrijkste 
oorzaken van obesitas, omdat deze extra calorieën voornamelijk als vet worden opgeslagen. 
De belangrijkste vetten in ons dieet zijn triglyceriden (TG) en cholesterol. Omdat vetten 
slecht oplosbaar zijn in bloed, worden ze als lipoproteinen vervoerd door het lichaam. Deze 
lipoproteinen zijn wel oplosbaar in bloed en vervoeren het vet van en naar verschillende 
organen. Ons lichaam maakt verschillende lipoproteinen die variëren in samenstelling en 
dichtheid. Chylomicronen zijn lipoproteinen die vetten na een maaltijd vanuit de darm naar 
andere organen zoals hart, spier, vet en lever transporteren. Wanneer er een tijdje niet gegeten is, 
worden er door de lever Zeer Lage Dichtheid Lipoproteinen (engels: VLDL) geproduceerd om 
het lichaam van vetten te voorzien. Zowel chylomicronen als VLDL bevatten voornamelijk TG 
en daarom worden deze deeltjes ook wel TG-rijke lipoproteinen genoemd. De TG deeltjes zijn 
te groot om als zodaning door de organen te worden opgenomen. Daarom breekt het enzym 
lipoprotein lipase (LPL) in het bloed het grote TG deeltje af tot 3 vetzuren (FA) en glycerol. Dit 
proces wordt lipolyse genoemd. Op deze wijze wordt TG als vetzuur en glycerol opgenomen 
door andere organen zoals wit vetweefsel (voor opslag), spier en hart (voor leveren van energie) 
en bruin vetweefsel (voor warmteproductie). In het desbetreffende orgaan worden deze 
vetzuren verbrand voor energie of weer omgezet in TG voor opslag. ‘Vrije’ vetzuren zijn toxisch 
en vandaar dat deze eenmaal in de organen weer direct worden omgezet in TG. 
Het wit vetweefsel speelt een centrale rol in de ontwikkeling van het metabool syndroom. 
Onder gezonde condities wordt een teveel aan calorieën voornamelijk opgeslagen als vet in 
het wit vetweefsel. Wanneer de energieinname langdurig het energieverbruik overschrijdt, 
moet het wit vetweefsel uitgebreid worden om de opslagcapaciteit te verhogen. Dit proces 
is echter gelimiteerd en wanneer de grenzen van dit proces zijn bereikt, zal vet ook worden 
opgeslagen in andere organen zoals spier en lever (dit wordt ectopic vet genoemd). Deze 
conditie verhoogt het risico op het krijgen van insulineresistentie. 
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CD36 is een eiwit dat zich bevindt aan de oppervlakte van cellen en helpt bij de opname 
van vetzuren in diverse organen, waaronder het witte vetweefsel. In hoofdstuk 2 hebben we 
de rol van CD36 in de cellen van het witte vetweefsel (adipocyten) onderzocht. We hebben 
hiervoor gebruik gemaakt van een muismodel dat geen CD36 heeft; de zogenaamde CD36-
deficiënte (CD36-/-) muis. Zowel de CD36-deficiënte muizen als de controle muizen gaven 
we een vetrijk dieet, zodat deze muizen obesitas ontwikkelden. De CD36-deficiënte muis 
nam minder in gewicht toe dan de controle muis. Tevens was de opname van vetzuren uit 
TG-rijke deeltjes in het witte vetweefsel verminderd in deze muis en de witte vetweefsels 
waren dientengevolge kleiner in de CD36-deficiënte muis, in vergelijking met de controle 
muis. Kleiner vetweefsel kan worden veroorzaakt door kleinere vetcellen of door een 
verminderd aantal vetcellen. We zagen dat in gonadaal (rond de geslachtsorganen), 
visceraal (buikholte) en subcutaan (onderhuids) wit vetweefsel de vetcellen kleiner waren. 
In het gonadale vetweefsel zagen we tevens een verminderd aantal cellen, wat veroorzaakt 
werd door een vermindering in het aantal zeer kleine vetcellen (diameter < 50 µm). Onze 
bevindingen impliceren dat CD36-deficiëntie de capaciteit van preadipocyten (voorlopers 
van adipocyten) om adipocyten te worden beperkt, aangezien we een verminderd aantal 
zeer kleine vetcellen waarnamen, maar een verhoogde verzameling van preadipocyten. 
Deze vermeende verminderde capaciteit van preadipocyten wordt niet veroorzaakt door 
een inherent ontwikkelingsdefect van CD36-deficiënte muizen, want in vitro experimenten 
lieten geen vermindering zien in intracellulaire vetstapeling in preadipocyten. Meestal 
laten kleinere vetcellen, zoals waargenomen in de CD36-deficiënte muis, minder lipolyse 
zien. Wij namen echter een verhoogde lipolyse waar in de adipocyten van CD36-deficiënte 
muizen. Samenvattend laten onze resultaten zien dat CD36 een belangrijke rol speelt in 
de functionaliteit van wit vetweefsel door het reguleren van zowel vetzuuropname als 
vetzuurafgifte. Dit heeft impact op de verdeling van vet (TG) over vetweefsel en andere 
organen. We hebben namelijk ook gezien dat de verminderde vetzuuropname in vetweefsel 
gepaard gaat met een verhoogde opname van vetzuren in de lever. Dat dit gevolgen heeft 
voor de insulinegevoeligheid blijkt uit de waarneming dat CD36-deficiënte muizen meer 
insuline resistent zijn in de lever dan controle muizen die een vetrijk dieet hebben gekregen. 
Uitbreiding van wit vetweefsel gaat vaak gepaard met infiltratie van immuun cellen in dit 
weefsel, wat resulteert in een milde ontsteking. Onder gezonde condities is dit van tijdelijke 
aard, maar gedurende chronisch energie overschot, kan deze milde ontsteking ook chronisch 
worden. Deze milde chronische ontsteking wordt ook wel metabole ontsteking genoemd, 
omdat verondersteld wordt dat deze ontsteking door een teveel aan voedingsstoffen wordt 
veroorzaakt. In obese mensen zijn stoffen die kenmerkend zijn voor ontsteking in licht 
verhoogde mate waargenomen in het bloedplasma. Deze milde systemische ontsteking in het 
lichaam is hoogstwaarschijnlijk het gevolg van metabole ontsteking in het vetweefsel en andere 
perifere organen zoals de lever. Metabole ontsteking lijkt een mogelijke oorzaak te zijn in de 
ontwikkeling van insulineresistentie. Uit eerder onderzoek kan worden afgeleid dat ontsteking, 
insulineresistentie en ontregeling van TG en FA metabolisme onderdeel zijn van een vicieuze 










Systemische ontsteking veroorzaakt een stijging van het plasma TG niveau, wat ook 
wel hypertriglyceridemie wordt genoemd. Eerder onderzoek met type 2 diabetes patiënten 
heeft laten zien dat behandeling met aspirine leidt tot een verlaging van bloedplasma TG. 
In hoofdstuk 3 hebben we het mechanisme onderzocht dat leidt tot een verlaging van 
hypertriglyceridemie door aspirine. Hiervoor hebben we APOC1 muizen, die vanwege een 
genetische mutatie een verhoogd bloedplasma TG gehalte hebben en controle muizen met 
een normaal bloedplasma TG gehalte gebruikt. Beide groepen gaven we een vetrijk dieet, met 
of zonder toevoeging van aspirine in het drinkwater. Aspirine verlaagde de NF-κB activiteit 
(kenmerkend voor ontsteking) in de lever van APOC1 en controle muizen. Bovendien 
verlaagde aspirine de plasma TG niveaus van hypertriglyceridemische APOC1 muizen. Deze 
TG verlaging kon niet worden verklaard door een verhoogde klaring (of te wel opname) van 
VLDL-TG door perifere organen. Echter, aspirine verlaagde de VLDL-TG productie door de 
lever. Hierbij bleef de productie van apoB, het belangrijkste eiwit van VLDL onveranderd, 
wat aangeeft dat de productie van het aantal VLDL deeltjes hetzelfde is, maar dat elk VLDL 
deeltje minder TG bevat. Vervolgens hebben we onderzocht op welke manier aspirine de 
VLDL-TG productie door de lever verminderd. We zagen dat aspirine geen verandering 
veroorzaakte in expressie van genen betrokken bij vetzuur oxidatie, lipogenese (vorming van 
TG) of VLDL productie. We konden wel aantonen dat er minder vetzuren vanuit het plasma 
door de lever werden ingebouwd in VLDL-TG. Dit was onafhankelijk van expressie van 
genen in de lever betrokken bij vetzuur opname en transport. Op basis van deze gegevens 
hebben we geconcludeerd dat aspirine hypertriglyceridemie kan verlagen door de VLDL-TG 
productie door de lever te verminderen, zonder hierbij het aantal geproduceerde deeltjes te 
veranderen. Onze resultaten suggereren dat de remming van ontsteking door aspirine, een 
interessante therapie kan zijn voor de behandeling van hypertriglyceridemie. 
In hoofdstuk 4 hebben we het effect van een plantaardig stof, genaamd META060, 
op gewichtsontwikkeling en insulinegevoeligheid onderzocht. In vitro is aangetoond dat 
META060 ontstekingsremmende effecten heeft. Om het effect van META060 te onderzoeken 
gebruikten we controle muizen die een normaal vetrijk dieet kregen of een vetrijk dieet 
aangevuld met META060. Onze resultaten lieten zien dat muizen die META060 kregen, 
beschermd waren tegen dieet-geïnduceerde obesitas.  Bovendien was de glucose tolerantie 
van muizen die META060 kregen hoger, wat duidt op een verbeterde insulinegevoeligheid. 
Deze bevindingen wijzen erop dat META060 potentiële therapeutische waarde heeft in de 
behandeling van obesitas en insulineresistentie. 
Wetenschappelijk onderzoek van de afgelopen jaren heeft duidelijk gemaakt dat het adaptieve 
immuun systeem een belangrijke rol speelt in het ontstaan van metabole ontsteking. Een toename 
van bepaalde ontstekingsbevorderende witte bloedcellen (T-lymphocyten en geactiveerde 
B-lymphocyten) in het vetweefsel van obese mensen duidt op de betrokkenheid van het adaptieve 
immuun systeem. Ook is er recent gevonden dat antilichamen gevormd door dieet-geïnduceerde 
obese muizen, na overdracht in muizen die zelf geen antilichamen aanmaken,  insulineresistentie 
kunnen veroorzaken. Dit geeft aan dat de humorale kant (B-lymphocyten & antilichamen) van 
het adaptieve immuun systeem  van belang is bij de ontwikkeling van het metabool syndroom. 
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In hoofdstuk 5 hebben we één van de mogelijke mechanismen onderzocht dat het 
effect van antilichamen op insulineresistentie zou kunnen verklaren. Antilichamen hebben 
een zogenaamd constant deel dat het Fc fragment wordt genoemd. Dit Fc fragment kan 
binden aan Fc receptoren die zich bevinden op cellen van het aangeboren immuun systeem 
zoals macrophagen, mest cellen en dendritische cellen. Waneer dit Fc fragment van een 
antilichaam bindt aan een Fc receptor (FcR) wordt er een reactie in de cellen van het 
aangeboren immuun systeem op gang gebracht die resulteert in inflammatoire processen. 
Wij hebben onderzocht of functionele FcR belangrijk zijn bij de ontwikkeling van dieet-
geïnduceerde obesitas, ontsteking in het wit vetweefsel en insulineresistentie. Dit hebben 
we gedaan door muizen die deficiënt zijn voor de zogenaamde γ-chain van de FcR op een 
vetrijk dieet te plaatsen en deze muizen te vergelijken met controle muizen op een vetrijk 
dieet. De γ-chain is van belang voor juiste expressie van FcR. Ook zorgt de γ-chain ervoor 
dat de FcR signalen kan doorgeven. Muizen die de γ-chain missen hebben onder andere 
een verminderde antilichaam response. Wij zagen dat FcR γ-chain deficiënte muizen 
minder in gewicht toenamen op een vetrijk dieet. Ook was er sprake van een verminderde 
inflammatie van wit vetweefsel en in perifere organen was de insulineresistentie als gevolg 
van het vetrijke dieet minder. Deze resultaten impliceren dat functionele FcR een rol spelen 
bij de ontwikkeling van metabool syndroom. 
Samengevat laten de studies in dit proefschrift zien dat het juist functioneren van wit 
vetweefsel en metabole ontsteking een belangrijke rol spelen in de ontwikkeling van obesitas 
en insulineresistentie. We laten zien dat CD36 belangrijk is voor het goed functioneren 
van adipocyten, waardoor het risico op ectopische vetafzetting in de lever kleiner wordt. 
Tevens tonen we aan dat functionele FcR betrokken kunnen zijn bij de ontwikkeling van 
obesitas, wit vetweefsel inflammatie en insulineresistentie, wat mogelijkheden biedt voor 
ontwikkeling van diagnostiek en nieuwe therapieën. Daarnaast laten we zien dat anti-
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